

Sociodemographic Disparities in Tafamidis Initiation and Clinical Outcomes in ATTR-CM Across the United States

Nicole Cyrille-Superville, MD,^{a,*} Hanna K. Gaggin, MD, MPH,^{b,*} Andrew M. Rosen, PhD,^c Margarita Udall, MPH,^c Liana Hennum, MPT, MHA,^c Bret Zeldow, PhD,^d Xingyu Gao, MPH,^d Elizabeth Nagelhout, PhD,^d Allison Keshishian, MPH,^d Margot K. Davis, MD, MSc^e

^aAtrium Health Sanger Heart & Vascular Institute Kenilworth, Charlotte, North Carolina, USA;

^bMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA;

^cBridgeBio Pharma, Inc., San Francisco, California, USA; ^dGenesis Research Group, Hoboken, New Jersey, USA; ^eThe University of British Columbia, Vancouver, BC, Canada.

*These authors contributed equally to this work.

medRxiv submission; June 12, 2026

Brief title: Disparities in tafamidis initiation and outcomes

ABSTRACT

BACKGROUND Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease. Sociodemographic factors may influence time to treatment initiation and resulting clinical outcomes, yet these relationships are poorly characterized.

OBJECTIVE Assess the effects of sex and race on tafamidis initiation and subsequent outcomes and their interaction with factors such as ATTR-CM type and social deprivation measures.

METHODS A retrospective cohort analysis was conducted using the US Komodo Healthcare Map[®] (01/2016-06/2024) among patients with amyloidosis, identified by ICD-10-CM diagnosis codes. Cumulative incidence of treatment initiation and survival probabilities for cardiovascular-related hospitalization (CVH) or death were estimated by Kaplan-Meier, stratified by sex and race. Cox proportional hazards models were fitted for both endpoints to estimate hazard ratios, adjusting for demographics and clinical characteristics.

RESULTS Of 11,311 patients identified, White and Black patients (n=9,223) were included in subsequent analyses. Within 12 months of diagnosis, White women had the lowest cumulative incidence of tafamidis initiation (11.4%), followed by Black women (22.0%), Black men (26.7%), and White men (31.0%). Event-free survival at 12 months was lowest in Black women (42.9%), followed by Black men (46.8%), White women (48.6%), and White men (54.4%). Median (95% CI) time to CVH or death was shortest for Black women (8.0 months [6.8-10.0]) followed by Black men (9.9 months [8.8-12.0]), White women (11.0 months [9.6-13.0]), and White men (15.0 months [14.0-16.0]).

CONCLUSIONS In this large, real-world cohort of US patients with ATTR-CM, sex and race contributed to disparities in tafamidis initiation and survival, underscoring compounded disparities in both access and outcomes.

KEY WORDS: ATTR-CM, transthyretin amyloid cardiomyopathy, amyloidosis, tafamidis, disparities, women

ABBREVIATIONS AND ACRONYMS

ATTR-CM = transthyretin amyloid cardiomyopathy; ATTRv-CM = variant transthyretin amyloid cardiomyopathy; ATTRwt-CM = wild-type transthyretin amyloid cardiomyopathy; CVH = cardiovascular-related hospitalization; HF = heart failure; ICD-10-CM = International Classification of Diseases, Tenth Revision, Clinical Modification; SDI = Social Deprivation Index; TTR = transthyretin.

INTRODUCTION

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening condition caused by cardiac deposition of pathogenic amyloid fibrils from misfolded transthyretin (TTR) protein.¹ There are 2 recognized clinical forms of ATTR-CM: wild-type ATTR-CM (ATTRwt-CM) and variant ATTR-CM (ATTRv-CM). ATTRv-CM is caused by pathological mutations in the *TTR* gene. ATTR-CM predominantly affects older adults; however, patients with ATTRv-CM typically present at a younger age than patients with ATTRwt-CM.¹ Despite advances in noninvasive imaging, growing disease awareness among clinicians, and the availability of disease-modifying treatments, ATTR-CM remains underdiagnosed, with diagnostic delays of up to 6 years after symptom onset.^{1,2} There are suggestions that disparities exist in diagnosis and time to treatment initiation, which may result in inequities in patient outcomes.^{1,3} It has been reported that Black patients present with more advanced disease at diagnosis compared with White patients, and women with ATTRv-CM are generally diagnosed approximately 7 years later than men with the same variants.^{4,5}

Tafamidis was the first and only disease-modifying treatment approved for ATTR-CM at the time of the study period. Tafamidis is most effective when initiated early.⁶ Real-world analyses and long-term extension studies confirm that earlier treatment initiation results in more sustained clinical benefits, yet treatment access and delays remain inequitable.⁷⁻¹⁰ In particular, the high annual cost of tafamidis (listed at \$277,709) poses a prohibitive burden for patients who are uninsured or underinsured, though patient assistance programs offer relief for those who can navigate this support.¹¹⁻¹⁴ Overall, the benefit of ATTR-CM treatment observed in clinical trials does not always translate into real-world settings, with persistently high rates of morbidity and mortality in populations with compounded barriers in access to care.^{9,10}

In addition to diagnostic delays, evidence suggests that sociodemographic factors, particularly sex and race, influence both time to treatment initiation and key clinical outcomes in ATTR-CM, including cardiovascular-related hospitalization (CVH) and all-cause mortality, yet these relationships are poorly characterized.^{4,15} The underrepresentation of these populations in pivotal trials limits our understanding; Black patients comprised only 14.3% of participants in the tafamidis phase 3 ATTR-ACT trial,^{6,7} yet they accounted for 2.4% of those with ATTRwt-CM and 51.9% of those with ATTRv-CM.^{6,7,16} Women have been similarly underrepresented in ATTR-CM trials, comprising only 8.7% of patients within the tafamidis arm.⁶ This is highly relevant in real-world clinical practice, given evidence that the true prevalence of disease in women has been underestimated. Some of the reasons for underdiagnosis in women may be due to the use of diagnostic criteria that incorporate a single threshold of left ventricular wall thickness for all individuals (ie, ≥ 12 mm), which may systematically miss female patients who generally have smaller hearts and therefore thinner ventricular walls.^{17,18} Differences between demographic groups in ATTRv-CM prevalence, age, disease stage at presentation, and disease phenotype suggest that universal treatment approaches may not address the specific needs of all patient populations.^{17,18} Using a large, real-world US cohort, we aimed to quantify sociodemographic disparities in time to tafamidis initiation and key clinical outcomes of CVH and all-cause mortality, hypothesizing that sex and race independently and synergistically determine treatment access and outcomes.

METHODS

STUDY DESIGN AND DATA SOURCE. A retrospective cohort study was conducted using the Komodo Healthcare Map[®], a US longitudinal claims database covering medical and

pharmacy claims across commercial and public payers. The observation window was January 1, 2016, through June 30, 2024, representing the period over which Komodo claims data were available. The first portion (2016-2019) served as a baseline look-back window requiring the absence of qualifying ATTR-CM diagnosis codes or tafamidis claims, thereby excluding prevalent ATTR-CM cases. The patient identification period was from May 3, 2019 (date of United States [US] Food and Drug Administration [FDA] approval of tafamidis for ATTR-CM), through June 30, 2024, representing the window for qualifying new ATTR-CM diagnoses had to occur for a patient with newly diagnosed ATTR-CM to enter the cohort. Thus, all included patients were diagnosed on or after the May 3, 2019, FDA approval date of tafamidis for ATTR-CM. The diagnosis index date was defined as the earliest occurrence of a qualifying ATTR-CM diagnosis code. The treatment index date was defined as the date of the initial tafamidis claim. Both the diagnosis and treatment index dates were required to occur during the patient identification period. Patients were followed until death, disenrollment, or end of the study period, whichever occurred first.

The Komodo Healthcare Map comprises medical and prescription claims data from several sources. It is characterized by proprietary partnership with >150 key national payers and consortiums, representing over 150 million payer lives. The database is representative of the US commercial-, Medicare-, and Medicaid-insured populations, and provides insights into the complete patient journey over time. The Komodo database complies with the Health Insurance Portability and Accountability Act. Given the anonymized, de-identified nature of the data, patient consent was not possible or required, and institutional review board approval to conduct this study was not necessary. Only aggregate cohort-level results were reported, without identification of any healthcare providers or healthcare facilities.

STUDY POPULATION. Patients were eligible if they were ≥ 18 years of age and had ≥ 2 claims for amyloidosis (International Classification of Diseases, Tenth Revision, Clinical Modification [ICD-10-CM] codes E85.0, E85.1, E85.2, E85.4, E85.82) occurring on separate days, along with ≥ 2 claims for a cardiac-related ICD-10-CM code during the identification period. Patients were required to have ≥ 6 months of continuous enrollment before the diagnosis index date and ≥ 1 day of enrollment after the diagnosis index date. Patients were excluded if they had > 1 claim (on separate days) for multiple myeloma (MM), light chain (AL) amyloidosis (E85.81), or hematopoietic stem cell transplantation any time during the study period, tafamidis use or ATTR-CM diagnosis any time before the diagnosis index date (to ensure a newly diagnosed population), or unknown sex.

VARIABLES. The primary outcome was time from ATTR-CM diagnosis to tafamidis initiation. The secondary outcome was time from diagnosis to CVH or all-cause death. Diagnosis was defined as the earliest of the 2 amyloidosis ICD-10-CM diagnosis codes, and the treatment index date was defined as the first tafamidis claim. CVH was defined as inpatient encounters with a CV-related ICD-10-CM code in any position (**Supplemental Table 1**); all-cause death was identified using claims-based mortality flags.

Patient characteristics evaluated included age, sex, race (self-identified), year of diagnosis, US region, and insurance type. Socioeconomic status was measured by Social Deprivation Index (SDI), a composite measure of area-level deprivation as it relates to social determinants of health, including poverty, education, employment, housing, transportation, and other household characteristics.¹⁹ This metric is used to quantify levels of disadvantage and inequities in small areas of the US. SDI scores range from 1 to 100, with a higher score

indicating higher social vulnerability. SDI was dichotomized as ≤ 80 (nondisadvantaged) vs > 80 (disadvantaged) in line with previous analyses.²⁰ ATTR-CM subtype (ATTRwt-CM or ATTRv-CM) was defined using ICD-10-CM coding algorithms. To be considered as having ATTRv-CM, a patient was required to have ≥ 2 heredofamilial amyloidosis codes (on separate days) during the identification period. If a patient had ATTRwt-CM codes and < 1 heredofamilial amyloidosis codes during the identification period, the patient was considered to have ATTRwt-CM. Baseline clinical variables assessed at or within 90 days of ATTR-CM diagnosis included chronic kidney disease, diabetes mellitus, hypertension, coronary artery disease, obesity, stroke, systolic heart failure (HF), and diastolic HF. Diastolic HF was included as a covariate to more accurately estimate the impact of sex and race on the target outcomes. The need for a loop diuretic was approximated by the loop diuretic (furosemide, torsemide, bumetanide) dose at baseline, categorized as none (no loop diuretic use), minor or mild (furosemide < 59 mg; torsemide < 29 mg; bumetanide < 1.4 mg), or moderate or severe (furosemide ≥ 60 mg; torsemide ≥ 30 mg; bumetanide ≥ 1.5 mg total daily dose).

STATISTICAL ANALYSIS. Baseline characteristics were summarized by sex and race. The Kaplan-Meier method, stratified by sex and race, was used to estimate cumulative incidence of tafamidis initiation at 3, 6, 9, and 12 months post-diagnosis, as well as to estimate event-free survival for CVH or all-cause death. Multivariable Cox proportional hazards models were fit to model time to tafamidis initiation and, separately, time to CVH or all-cause death. White men served as the reference population in both Cox proportional hazards models. Covariates included sex, race, SDI, ATTR-CM type, year of diagnosis, age at diagnosis, US region, insurance type, need for a loop diuretic, and select comorbidities (chronic kidney disease, chronic obstructive

pulmonary disease, diabetes mellitus, diastolic HF, hypertension, obesity, stroke, systolic HF). Prespecified interaction terms were sex $\times$ race, sex $\times$ SDI, and race $\times$ ATTR-CM type. Pairwise differences by race and sex (both overall and stratified by ATTR-CM type and SDI) were estimated using least square means derived from these models, which estimate adjusted survival outcomes by averaging over all other model covariates. Comparisons are presented using hazard ratios (HRs) and nominal *P* values ($P < 0.001$ was considered significant to account for multiple pairwise comparisons across sex, race, ATTR-CM subtype, and SDI strata).

RESULTS

PATIENTS. A total of 59,330 patients with amyloid codes were identified during the study period; 11,311 met eligibility criteria after exclusions (**Supplemental Figure 1**), including a priori exclusion of 953 patients with AL amyloidosis alone, 653 with MM alone, and 1,851 with both. Overall, 63.9% of patients were male, 52.0% were White, 29.6% were Black, 18.4% were other/unknown races, and 91.3% had ATTRwt-CM. Mean (SD) age at diagnosis was 73.5 (11.6) years for men and 72.4 (13.1) years for women. Only White and Black patients ($n=9,223$) were included in the remaining analyses due to the small sample size and heterogeneity of other groups. In this population, 64.9% of patients were male, 63.7% were White, and 36.3% were Black (**Table 1**). Black patients were younger (mean [SD], 71.1 [12.6] years vs 76.1 [10.3] years), had higher rates of ATTRv-CM (12.6% vs 6.0%), had a higher degree of social deprivation (SDI 81-100, 39.7% vs 12.5%), and had a higher rate of moderate-to-severe loop diuretic use (furosemide ≥ 60 mg; 19.2% vs 12.3%) than White patients, respectively. In addition, more Black patients lived in the South compared with White patients (33.7% vs 17.4%, respectively). Substantially greater proportions of Black patients had chronic kidney disease

(58.9% vs 41.5%), diabetes mellitus (52.4% vs 33.3%), and systolic HF (47.5% vs 33.0%) compared with White patients, respectively. Women (n=3,241) had a higher degree of social deprivation (SDI 81-100, 26.1% vs 20.3%) and greater proportions had stroke (37.4% vs 26.2%), while smaller proportions had COPD (50.5% vs 62.0%) and systolic HF (31.6% vs 41.9%) compared with men (n=5,982).

TIME TO TAFAMIDIS INITIATION. Women had a significantly lower cumulative incidence of tafamidis initiation compared with men ($P<0.001$). Within 3 months of diagnosis, the cumulative incidence of tafamidis initiation was 9.9% among women and 19.9% among men. This gap persisted at 12 months, with the cumulative incidence of tafamidis initiation among women and men at 14.5% and 28.5%, respectively. White patients had a higher cumulative incidence of tafamidis initiation within 3 months of diagnosis compared with Black patients (18.3% vs 16.0%). There was narrowing of this gap by 12 months (25.1% vs 24.6%); however, when stratified by both race and sex, White men had the highest cumulative incidence of tafamidis initiation at 12 months (31.0%), followed by Black men (26.7%), Black women (22.0%), and White women (11.4%) (**Figure 1**).

Results from the Cox model of time to tafamidis initiation are presented in **Supplemental Table 2**. Overall, pairwise contrasts of time to tafamidis initiation by race and sex demonstrated significant disparities, with White women having the longest time to tafamidis initiation after adjusting for covariates ($P<0.001$) (**Supplemental Table 3**). White women initiated tafamidis later than White men (HR: 0.39 [95% CI: 0.33-0.45]; $P<0.001$) as well as both Black men (HR: 2.83 [95% CI: 2.38-3.37]; $P<0.001$) and Black women (HR: 2.10 [95% CI: 1.73-2.54]; $P<0.001$). Black women initiated tafamidis later than both Black men (HR: 0.74 [95% CI: 0.64-

0.86]; $P < 0.001$) and White men (HR: 0.81 [95% CI: 0.71-0.93]; $P = 0.003$). These patterns were largely consistent across ATTR-CM subtypes, with notable exceptions: Black men initiated tafamidis earlier than White men (HR: 1.74 [95% CI: 1.32-2.30]; $P < 0.001$) only among those with ATTRv-CM, and Black women initiated tafamidis later than White men (HR: 0.78 [95% CI: 0.68-0.90]; $P < 0.001$) only among those with ATTRwt-CM.

Across SDI strata for low ($SDI \leq 80$) and high social vulnerability ($SDI > 80$), White women initiated tafamidis later than White men, while both Black men and Black women initiated tafamidis earlier compared with White women (**Supplemental Table 3**).

TIME TO CVH OR DEATH. Kaplan-Meier curves demonstrated significant differences in time to CVH or death stratified by race and sex ($P < 0.001$) (**Figure 2**). Event-free survival at 12 months was lowest for Black women (42.9%), followed by Black men (46.8%), White women (48.6%), and White men (54.4%). Accordingly, Black women had the shortest median (95% CI) time to CVH or death (8.0 months [6.8-10.0]), followed by Black men (9.9 months [8.8-12.0]), White women (11.0 months [9.6-13.0]), and White men (15.0 months [14.0-16.0]) (**Table 2**).

Results from the Cox model of time to CVH or death are presented in **Supplemental Table 4**. Overall, pairwise contrasts of race and sex for time to CVH or death demonstrated that both White women (HR: 1.15 [95% CI: 1.07-1.25]; $P < 0.001$) and Black women (HR: 1.16 [95% CI: 1.07-1.26]; $P < 0.001$) had a significantly greater risk of CVH or death compared with White men (**Supplemental Table 5**). Patterns were consistent across ATTR-CM subtypes, with the exception of Black men with ATTRv-CM, who had a significantly lower risk of CVH or death compared with White women with ATTRv-CM (HR: 0.69 [95% CI: 0.56-0.86]; $P < 0.001$). Among patients with low social vulnerability ($SDI \leq 80$), sex disparities persisted, while there

were no significant differences in patients with high social vulnerability (SDI >80) when compared by sex and race (**Supplemental Table 5**).

DISCUSSION

In this national cohort of more than 11,000 patients with ATTR-CM, marked sociodemographic differences were observed in tafamidis initiation and subsequent clinical outcomes (**Central Illustration**). Our major findings include: 1) Women were significantly less likely than men to initiate tafamidis within 12 months of diagnosis, with White women having the lowest uptake. Black women had higher tafamidis initiation rates than White women, but remained disadvantaged compared with men. 2) Survival probabilities for CVH or death were lower among female patients and among Black patients. 3) There were notable differences in factors associated with time to tafamidis initiation compared with those associated with the clinical outcomes of CVH or death. During a time of increased disease awareness, less invasive diagnostic techniques, and available disease modifying therapies, inequities in the treatment and clinical outcomes of women and Black patients is a serious cause for concern.

Approximately 36% of patients in the overall cohort were women. This is greater than the proportion of women observed in the Cardiac Amyloidosis Registry Study (CARS; 13%), but is more closely aligned with the proportion of women observed in the active ascertainment cohort of the Screening for Cardiac Amyloidosis with Nuclear Imaging in Minority Populations study (SCAN-MP; 31%), which had a recruitment target of 50% for women.²¹⁻²³ The observation that White women had the lowest tafamidis initiation rates is particularly striking and suggests sex-related barriers independent of race. First, despite prospective studies of patients with heart failure showing closer to equal proportions of women and men with ATTR-CM by post- and

ante-mortem analyses, ATTR-CM is wrongly considered a predominantly male disease, and there is a lack of real-world data on outcomes in female patients.^{24,25} Systematic underscreening, underdiagnosis, and underrepresentation in clinical trials have left the literature on sex differences in ATTR-CM limited and inconsistent, compounded by a lack of real-world data on outcomes in women. For example, some prior cohorts reported a higher age at ATTR-CM diagnosis in women compared with men,^{17,18,26} although this pattern was not observed in the present study. Similarly, reported differences in disease severity between sexes have been attenuated in studies accounting for body size.^{17,18,27}

Our cohort offers an opportunity to address part of this data gap. Women have been underrepresented in ATTR-CM phase 3 clinical trials, accounting for <10% of enrolled patients,^{6,28,29} compared with 36% in the current cohort analysis. This higher representation may provide observations about female patients that may be more reflective of real-world clinical practice. The higher initiation of tafamidis among Black women compared with White women may reflect greater clinical vigilance due to awareness of the greater potential for Black individuals to be carriers of the p.Val142Ile variant, which is found almost exclusively in individuals of West African descent,³⁰⁻³² though absolute rates remained lower than in men. Notably, 7.1% of White women in our cohort had ATTRv-CM. Together, these results underscore the need to address both structural and clinical drivers of unequal access.

Barriers to equitable quality of care and health outcomes, whether caused by affordability, technical literacy, or racism and bias, continue to pose a problem in the US.³³ Despite the progressive increase in tafamidis initiation from 3 to 12 months post-diagnosis for all groups, women had higher risk of CVH or death at 12 months compared with White men. This disparity persisted after adjusting for tafamidis initiation, indicating that later-stage recognition,

referral gaps, and limited access to advanced therapies may play important roles. More research is needed to identify additional mediators of the association between sex and clinical outcomes. The pivotal ATTR-ACT trial established tafamidis as the initial ATTR-CM disease modifying therapy which reduced mortality and hospitalizations,⁶ with the long-term extension studies showing sustained survival benefit with early treatment initiation.⁹ Real-world studies have confirmed that delays in treatment initiation diminish survival benefits.¹⁰ Our results suggest that inequities in tafamidis access may translate into clinically meaningful survival gaps. The ATTR-CM subtype analysis revealed an important nuance regarding racial disparities in disease outcomes. Although Black patients with ATTRv-CM had lower adjusted risk of CVH or death compared with White patients with variant disease, raw survival analyses showed that Black women overall had the lowest 12-month event-free survival. This apparent discrepancy may reflect the influence of later-stage diagnosis and residual confounding not fully captured in claims-based adjustments (eg, physician experience, patient functional status, or disease severity). Future prospective studies incorporating imaging and biomarker staging will be required to clarify these differences and better understand how sex, race, and genetic subtype interact to shape outcomes.

Our findings expand on prior reports of delayed diagnosis and worse clinical outcomes in underrepresented minorities with ATTR-CM. A retrospective analysis of 231 patients with ATTR-CM demonstrated that Afro-Caribbean patients had more advanced disease at the time of diagnosis and experienced poor outcomes more frequently than White patients.⁴ The current analysis shows that Black patients had higher rates of comorbidities than White patients. While higher mortality rates have been reported in counties near amyloid centers, southern states, despite having a higher proportion of Black patients than other US regions, reported the lowest

mortality rates. This is likely due to disparities in the diagnosis of ATTR-CM among Black patients.¹⁵ Earlier recognition of ATTR-CM in women and Black patients is critical, supported by guideline-directed diagnostic pathways.^{34,35} Clinical trials must prioritize inclusive enrollment to strengthen generalizability and reduce uncertainty that contributes to treatment inequity.^{36,37} Implementation studies are needed to evaluate strategies that close gender and racial gaps in tafamidis initiation and improve long-term outcomes.

Our analysis demonstrated a lack of SDI effect on tafamidis initiation, but there was an effect on clinical outcomes. Women with low social vulnerability had a greater risk of CVH or death compared with White men, while there was no difference in patients with high social vulnerability. This paradox may be partly explained by the use of patient assistance programs to acquire tafamidis, the status for which could not be discerned with the study data source. Eligibility criteria for patient assistance programs create a nonlinear relationship between income and treatment access: the lowest-income patients may obtain tafamidis through patient assistance programs, while middle-income patients—who exceed patient assistance program thresholds but cannot afford high out-of-pocket costs—face the greatest barriers. Prior research shows that 35% of patients receive tafamidis solely through the patient assistance program, with an additional 14% using both Medicare and the patient assistance program.¹³ Given that patients receiving tafamidis through the patient assistance program were not indicated in the Komodo database, we cannot determine the true treatment patterns across income levels in our cohort. This may explain why socioeconomic factors did not modify gender gaps while sex and race disparities remained prominent.

LIMITATIONS. Several limitations merit consideration. Claims-based data are vulnerable to diagnostic misclassification and the results may underrepresent undocumented variables. Further, without a published validated ATTR-CM coding algorithm,³⁸ additional limitations include the limited ability to discern ATTR-CM genotype, as the relevant codes are relatively new, not widely or consistently used, and not linked to follow-up genetic testing. Although patients with codes for AL amyloidosis or MM were excluded a priori, residual AL-CM contamination cannot be fully ruled out among patients coded with nonspecific amyloidosis codes (E85.4, E85.89), particularly those who did not receive disease-specific therapy. Disease severity could not be directly assessed; the loop diuretic dose was used as a proxy in the absence of imaging or biomarker data. There was also a lack of data on biomarkers, disease staging, and disease severity in the adjustments for the multivariable analyses. Our primary models estimated the direct disparity attributable to race and sex, adjusting for clinical phenotype variables—diastolic and systolic HF and loop diuretic dose—that typically reflect disease expression at or near the time of ATTR-CM diagnosis. This adjustment helps isolate disparities that are independent of measured need for a loop diuretic and phenotype, but may attenuate disparities that operate through later presentation, diagnostic coding, or clinical labeling that are themselves influenced by severity. Mortality ascertainment from claims may underestimate events, and the limitations of claims-based death capture should be considered when interpreting the all-cause death component of the composite endpoint. Residual confounding, including provider practice patterns and patient preferences, cannot be excluded. We could not discern patients who may have received tafamidis through the patient assistance program and as mentioned earlier, this may have impacted our estimates of the association between SDI and tafamidis use. Patient data

were limited in parts of the Western US due to lack of Komodo Healthcare Map data captured in closed healthcare systems. Finally, multiple ad hoc comparisons can inflate the type I error.

CONCLUSIONS

Sociodemographic factors significantly influenced tafamidis initiation and clinical outcomes in ATTR-CM. Women, particularly White women, were least likely to initiate tafamidis, while Black women had the poorest survival, underscoring compounded disparities in both access and outcomes. These findings, informed by real-world evidence, reveal inequities in access to care leading to poor clinical outcomes, and strategies need to be identified to close the equity gap in ATTR-CM care and patient outcomes. Addressing these inequities will require coordinated approaches spanning diagnosis, prescribing, payer policy, and research inclusivity, to ensure equitable delivery of disease-modifying treatment in ATTR-CM. Our findings may increase awareness of critical demographic disparities in ATTR-CM treatment and outcomes and identify opportunities to improve the equity in ATTR-CM treatment access, time to treatment initiation, and ultimately optimize clinical outcomes for all patients with ATTR-CM.

DATA AVAILABILITY

The data that support the findings of this study were used under license from Komodo Health[®] and derived from the Komodo Healthcare Map[®]. Due to data use agreements and its proprietary nature, restrictions apply regarding the availability of the data. Further information is available from the sponsor of the study, BridgeBio Pharma, Inc., San Francisco, CA, USA.

CLINICAL PERSPECTIVES

- **COMPETENCY IN MEDICAL KNOWLEDGE:** In this large, real-world analysis of the effects of sex and race on tafamidis initiation and clinical outcomes in US patients with ATTR-CM, White and Black women had lowest cumulative incidence of treatment initiation, followed by Black and White men, and Black women had the lowest event-free survival at 12 months and shortest time to CVH or death, followed by Black men, White women, and White men.
- **TRANSLATIONAL OUTLOOK:** These real-world data reveal compounded disparities in both access to care and poor clinical outcomes for patients, particularly in women, with ATTR-CM. Strategies to close the equity gap in ATTR-CM care are needed.

ACKNOWLEDGMENTS

This study was funded by BridgeBio, Pharma, Inc. (San Francisco, CA, USA). All authors contributed to and approved the manuscript. Writing and editorial assistance were provided by Anne Jacobson, MPharm, CMPP, of The Lockwood Group (Stamford, CT, USA), funded by BridgeBio Pharma, Inc.

AUTHOR CONTRIBUTIONS

All the authors participated in the conception and design of the study and in the analysis and interpretation of data. All the authors participated in the preparation and final approval of the manuscript.

DISCLOSURES

NC-S: Received honoraria from Alnylam Pharmaceuticals, BridgeBio Pharma, Inc., and Pfizer;

HG: Received research grant support from Akcea Therapeutics (Ionis

Pharmaceuticals/AstraZeneca), Alnylam Pharmaceuticals, BridgeBio Pharma, Inc., eMyosound,

Pfizer, and Roche Diagnostics; consulting income from Alnylam Pharmaceuticals, AstraZeneca,

BridgeBio Pharma, Inc., eMyosound, Merck, Novo Nordisk, Pfizer, and TD Cowen; stock option

for Eko Health; research payments for clinical endpoint committees from Baim Institute for

Clinical Research for Abbott, Beckman Coulter Diagnostics, Innolife, and Siemens, and from

ACI/WCG Clinical for Abbott Laboratories and Alexion Pharmaceuticals;

reimbursement/honoraria from Inova Schar Heart and Vascular; and support from Women As

One for the 2025 Women As One Mentorship Awards; **AMR** and **LH:** Employees and

stockholders of BridgeBio Pharma, Inc.; **MU:** Employee and stockholder of BridgeBio Pharma,

Inc., and stockholder of Pfizer; **BZ, XG, EN, and AK:** Contractors for BridgeBio Pharma, Inc.;

MKD: Received honoraria from Alnylam Pharmaceuticals, AstraZeneca, BridgeBio Pharma,

Inc., Novo Nordisk, and Pfizer; and research grant support from Pfizer.

REFERENCES

1. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. *J Am Coll Cardiol*. 2019;73(22):2872-2891.
2. Rozenbaum MH, Large S, Bhambri R, et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. *Cardiol Ther*. 2021;10(1):141-159.
3. González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. *Eur Heart J*. 2015;36(38):2585-2594.
4. Ngouchet Nouhossi JL, Minga I, Szasz T, et al. Disparities in diagnosis and outcomes in American patients with transthyretin cardiac amyloidosis. *Int J Cardiovasc Imaging*. 2025;41(8):1487-1496.
5. Batra J, Rosenblum H, Defilippis EM, et al. Sex differences in the phenotype of transthyretin cardiac amyloidosis due to Val122Ile mutation: insights from noninvasive pressure-volume analysis. *J Card Fail*. 2021;27(1):67-74.
6. Maurer MS, Schwartz JH, Gundapaneni B, et al.; for the ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. *N Engl J Med*. 2018;379(11):1007-1016.
7. Damy T, Garcia-Pavia P, Hanna M, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. *Eur J Heart Fail*. 2021;23(2):277-285.

8. Garcia-Pavia P, Sultan MB, Gundapaneni B, et al. Tafamidis efficacy among octogenarian patients in the phase 3 ATTR-ACT and ongoing long-term extension study. *JACC Heart Fail.* 2024;12(1):150-160.
9. Elliott P, Drachman BM, Gottlieb SS, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. *Circ Heart Fail.* 2022;15(1):e008193.
10. Hussain K, Macrinici V, Wathen L, et al. Impact of tafamidis on survival in a real-world community-based cohort. *Curr Probl Cardiol.* 2022;47(12):101358.
11. Stein-Merlob AF, Swier R, Vucicevic D. Evolving strategies in cardiac amyloidosis: from mechanistic discoveries to diagnostic and therapeutic advances. *Cardiol Clin.* 2025;43(1):93-110.
12. Krumholz HM, Kittleson MM, Kadakia KT. A breakthrough with a burden: access, affordability, and the future of ATTR-CM therapy. *J Am Coll Cardiol.* 2025;86(6):409-411.
13. Chung H, Cantu C, Pankratova C, et al. Adherence and persistence to tafamidis treatment among Medicare beneficiaries in the presence of a patient assistance program. *Sci Rep.* 2024;14(1):16261.
14. Tafamidis. RED BOOK Online. IBM Micromedex [database online]. Truven Health Analytics/IBM Watson Health; 2020. Accessed October 30, 2025.
<https://www.micromedexsolutions.com/>.
15. Alexander KM, Orav J, Singh A, et al. Geographic disparities in reported US amyloidosis mortality from 1979 to 2015: potential underdetection of cardiac amyloidosis. *JAMA Cardiol.* 2018;3(9):865-870.

16. Rapezzi C, Elliott P, Damy T, et al. Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT. *JACC Heart Fail.* 2021;9(2):115-123.
17. Aimo A, Panichella G, Garofalo M, et al. Sex differences in transthyretin cardiac amyloidosis. *Heart Fail Rev.* 2024;29(2):321-330.
18. Patel RK, Ioannou A, Razvi Y, et al. Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis. *Eur J Heart Fail.* 2022;24(12):2355-2363.
19. Robert Graham Center. Social Deprivation Index. Accessed November 7, 2025. <https://www.graham-center.org/maps-data-tools/social-deprivation-index.html>.
20. Gill TM, Zang EX, Murphy TE, et al. Association between neighborhood disadvantage and functional well-being in community-living older persons. *JAMA Intern Med.* 2021;181(10):1297-1304.
21. Stern LK, Grodin JL, Maurer MS, et al. The Cardiac Amyloidosis Registry Study (CARS): rationale, design and methodology. *J Card Fail.* 2024;30(5):669-678.
22. Chan N, Einstein AJ, Teruya S, et al. The impact of active ascertainment on sex-specific differences in the prevalence and phenotype of transthyretin cardiac amyloidosis: the screening for cardiac amyloidosis with nuclear imaging in minority populations study. *Am J Cardiol.* 2025;237:60-64.
23. Ruberg FL, Blaner WS, Chiuzaan C, et al. Design and rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) study. *J Am Heart Assoc.* 2023;12(8):e028534.

24. Bruno M, Castaño A, Burton A, Grodin JL. Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges. *Heart Fail Rev.* 2021;26(1):35-45.
25. Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. *JACC Heart Fail.* 2014;2(2):113-122.
26. Campbell CM, LoRusso S, Dispenzieri A, et al. Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). *Cardiol Ther.* 2022;11(3):393–405.
27. Aimo A, Tomasoni D, Porcari A, et al. Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis. *Eur J Heart Fail.* 2023;25(4):510-514.
28. Gillmore JD, Judge DP, Cappelli F, et al.; for the ATTRIBUTE-CM Investigators. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. *N Engl J Med.* 2024;390(2):132-142.
29. Fontana M, Berk JL, Gillmore JD, et al.; for the HELIOS-B Trial Investigators. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. *N Engl J Med.* 2025;392(1):33-44.
30. Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. *Amyloid.* 2015;22(3):171-174.

31. Chandrashekar P, Alhuneafat L, Mannello M, et al. Prevalence and outcomes of p.Val142Ile *TTR* amyloidosis cardiomyopathy: a systematic review. *Circ Genom Precis Med*. 2021;14(5):e003356.
32. Poli L, Labella B, Cotti Piccinelli S, et al. Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy. *Front Neurol*. 2023;14:1242815.
33. Chen AM. Barriers to health equity in the United States of America: can they be overcome? *Int J Equity Health*. 2025;24(1):39.
34. Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. *Circ Heart Fail*. 2019;12(9):e006075.
35. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. *Circulation*. 2016;133(24):2404-2412.
36. Shankar B, Yanek L, Jefferson A, et al. Race and socioeconomic status impact diagnosis and clinical outcomes in transthyretin cardiac amyloidosis. *JACC CardioOncol*. 2024;6(3):454-463.
37. Spencer-Bonilla G, Njoroge JN, Pearson K, Witteles RM, Aras MA, Alexander KM. Racial and ethnic disparities in transthyretin cardiac amyloidosis. *Curr Cardiovasc Risk Rep*. 2021;15(6):8.
38. Coleman CI, Martinez R, Torres SA. Methods of identifying transthyretin amyloid cardiomyopathy in secondary data sources: a systematic review. *Curr Med Res Opin*. 2025;41(11):2013-2024.

FIGURE LEGENDS

Figure 1 Cumulative Incidence of Tafamidis Initiation by Sex and Race. Diagnosis was defined as the earliest occurrence of the 2 ATTR-CM diagnosis codes, and the treatment index date was defined as the first tafamidis claim. The table shows the number of patients at risk (not yet on treatment) and cumulative events (treatment initiations) at 0, 10, 20, 30, 40, and 50 months. ATTR-CM = transthyretin amyloid cardiomyopathy; HR = hazard ratio.

Figure 2 Time to CVH or Death by Sex and Race. Diagnosis was defined as the earliest occurrence of the 2 ATTR-CM diagnosis codes, CVH was defined as inpatient encounters with a cardiovascular-related ICD-10-CM code, and death was identified using claims-based mortality flags. The table shows the number of patients at risk (who have not yet experienced CVH or death) and cumulative events (CVH or death) at 0, 10, 20, 30, 40, and 50 months. ATTR-CM = transthyretin amyloid cardiomyopathy; CVH = cardiovascular-related hospitalization; HR = hazard ratio; ICD-10-CM = International Classification of Diseases, Tenth Revision, Clinical Modification.

CENTRAL ILLUSTRATION Disparities in Tafamidis Initiation and Outcomes

In this retrospective cohort analysis of 9,223 White and Black patients with ATTR-CM in the US, White women had the lowest cumulative incidence of tafamidis initiation within 12 months of diagnosis, followed by Black women, Black men, and White men. Black women had the lowest event-free survival at 12 months and shortest median time to CVH or death, followed by Black men, White women, and White men. Strategies to close the equity gap in ATTR-CM care are needed. ATTR-CM = transthyretin amyloid cardiomyopathy; CKD = chronic kidney disease;

CVH = cardiovascular-related hospitalization; COPD = chronic obstructive pulmonary disease;

SDI = Social Deprivation Index.

TABLES

Table 1 Baseline Demographics and Patient Characteristics by Sex and Race^a

	Overall		Men		Women	
Characteristic	White (n=5,877)	Black (n=3,346)	White (n=4,125)	Black (n=1,857)	White (n=1,752)	Black (n=1,489)
Age at diagnosis						
Mean (SD), years	76.1 (10.3)	71.1 (12.6)	76.5 (9.6)	70.3 (12.2)	75.1 (11.6)	72.2 (13.0)
ATTR-CM type, n (%)						
ATTRwt-CM	5,527 (94.0)	2,923 (87.4)	3,899 (94.5)	1,614 (86.9)	1,628 (92.9)	1,309 (87.9)
ATTRv-CM	350 (6.0)	423 (12.6)	226 (5.5)	243 (13.1)	124 (7.1)	180 (12.1)
US region, n (%)						
Northeast	2,519 (42.9)	1,094 (32.7)	1,843 (44.7)	558 (30.1)	676 (38.6)	536 (36.0)
Midwest	1,455 (24.8)	925 (27.6)	1,019 (24.7)	545 (29.4)	436 (24.9)	380 (25.5)
South	1,022 (17.4)	1,129 (33.7)	665 (16.1)	644 (34.7)	357 (20.4)	485 (32.6)
West	878 (14.9)	197 (5.9)	596 (14.5)	109 (5.9)	282 (16.1)	88 (5.9)
Year of diagnosis, n (%)^b						
2019	626 (10.7)	361 (10.8)	435 (10.6)	194 (10.5)	191 (10.9)	167 (11.2)
2020	925 (15.7)	552 (16.5)	621 (15.1)	303 (16.3)	304 (17.4)	249 (16.7)
2021	1,187 (20.2)	730 (21.8)	833 (20.2)	401 (21.6)	354 (20.2)	329 (22.1)
2022	1,305 (22.2)	813 (24.3)	910 (22.1)	464 (24.5)	395 (22.6)	349 (23.4)
2023	1,394 (23.7)	711 (21.3)	1,011 (24.5)	396 (21.3)	383 (21.9)	315 (21.2)
2024	440 (7.5)	179 (5.4)	315 (7.6)	99 (5.3)	125 (7.1)	80 (5.4)
Medical insurance type, n (%)						
Medicare	4,925 (83.8)	2,467 (73.7)	3,473 (84.2)	1,336 (71.9)	1,452 (82.9)	1,131 (76.0)
Commercial	658 (11.2)	408 (12.2)	482 (11.7)	273 (14.7)	176 (10.1)	135 (9.1)
Medicaid	289 (4.9)	470 (14.1)	166 (4.0)	247 (13.3)	123 (7.0)	223 (15.0)
Unknown	5 (<0.1)	1 (<0.1)	4 (0.1)	1 (<0.1)	1 (<0.1)	0

SDI, n (%)						
≤80	5,105 (86.9)	2,012 (60.1)	3,606 (87.4)	1,134 (61.1)	1,499 (85.6)	878 (59.0)
>80	732 (12.5)	1,327 (39.7)	495 (12.1)	719 (38.8)	237 (13.7)	608 (40.9)
Unknown	40 (0.7)	7 (0.2)	24 (0.6)	4 (0.2)	16 (0.9)	3 (0.2)
Total daily equivalent oral furosemide use, n (%)						
No loop diuretic use	2,875 (48.9)	1,484 (44.4)	1,886 (45.7)	807 (43.5)	989 (56.5)	677 (45.5)
Furosemide <59 mg	2,280 (38.8)	1,219 (36.4)	1,673 (40.6)	665 (35.8)	607 (34.6)	554 (37.2)
Furosemide ≥60 mg	722 (12.3)	643 (19.2)	566 (13.7)	385 (20.7)	156 (8.9)	258 (17.3)
Comorbidity, n (%)						
CKD	2,437 (41.5)	1,971 (58.9)	1,774 (43.0)	1,128 (60.7)	663 (37.8)	843 (56.6)
COPD	3,478 (59.2)	1,867 (55.8)	2,631 (63.8)	1,078 (58.1)	847 (48.3)	789 (52.3)
Diabetes mellitus	1,958 (33.3)	1,752 (52.4)	1,379 (33.4)	962 (51.8)	579 (33.1)	790 (53.1)
Diastolic heart failure	2,913 (49.6)	1,690 (50.5)	2,024 (49.1)	871 (46.9)	889 (50.7)	819 (55.0)
Hypertension	4,984 (84.8)	3,094 (92.5)	3,486 (84.5)	1,705 (91.8)	1,498 (85.5)	1,389 (93.3)
Obesity	1,423 (24.2)	1,102 (32.9)	938 (22.7)	546 (29.4)	485 (27.7)	556 (37.3)
Stroke	1,692 (28.8)	1,087 (32.5)	1,031 (25.0)	537 (28.9)	661 (37.7)	550 (36.9)
Systolic heart failure	1,941 (33.0)	1,589 (47.5)	1,514 (36.7)	991 (53.4)	427 (24.4)	598 (40.2)

^aOnly White and Black patients were included in this analysis; patients of other races were excluded (n=2088).

^bThe patient identification period was from May 3, 2019, to June 30, 2024.

ATTR-CM = transthyretin amyloid cardiomyopathy; ATTRv-CM = variant transthyretin amyloid cardiomyopathy; ATTRwt-CM = wild-type transthyretin amyloid cardiomyopathy; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; SD = standard deviation; SDI = Social Deprivation Index.

Table 2 CVH or Death by Sex and Race

Characteristic	White men (n=4,125)	Black men (n=1,857)	White women (n=1,752)	Black women (n=1,489)
Events, n (%)				
CVH	1,962 (47.6)	1,052 (56.7)	947 (54.1)	863 (58.0)
Death	685 (16.6)	237 (12.8)	299 (17.1)	195 (13.1)
CVH or death	2,183 (52.9)	1,104 (59.5)	1,013 (57.8)	903 (60.6)
Median (95% CI) time to CVH or death, months	15.0 (14.0-16.0)	9.9 (8.8-12.0)	11.0 (9.6-13.0)	8.0 (6.8-10.0)
Patients free from CVH or death, % (95% CI)				
3 months	76.1 (74.8-77.4)	69.5 (67.4-71.7)	70.2 (68.1-72.4)	64.8 (62.4-67.4)
6 months	66.9 (65.4-68.4)	59.8 (57.6-62.2)	60.5 (58.2-62.9)	54.1 (51.5-56.8)
9 months	60.4 (58.8-62.0)	51.9 (49.6-54.4)	53.2 (50.8-55.8)	48.7 (46.1-51.5)
12 months	54.4 (52.8-56.1)	46.8 (44.4-49.3)	48.6 (46.1-51.2)	42.9 (40.2-45.8)

CVH = cardiovascular-related hospitalization.

FIGURES

Figure 1 Cumulative Incidence of Tafamidis Initiation by Sex and Race







Figure 2 Time to CVH or Death by Sex and Race



CENTRAL ILLUSTRATION Disparities in Tafamidis Initiation and Outcomes



SUPPLEMENTAL APPENDIX

Sociodemographic Disparities in Tafamidis Initiation and Clinical Outcomes in ATTR-CM Across the United States

Supplemental Table 1 CV-related ICD-10-CM Codes Used in the Study.....	2
Supplemental Table 2 Predictors of Time to Tafamidis Initiation by Socioeconomic Interactions.....	40
Supplemental Table 3 Pairwise Contrasts of Sex and Race for Time to Tafamidis Initiation.....	42
Supplemental Table 4 Predictors of Time to CVH or Death by Socioeconomic Interactions.....	43
Supplemental Table 5 Pairwise Contrasts of Sex and Race for Time to CVH or Death by SDI Score.....	45
Supplemental Figure 1 CONSORT Flow Diagram.....	46

Supplemental Table 1 CV-related ICD-10-CM Codes Used in the Study

ICD10 CODES	LEVEL 2 DESCRIPTION	CATEGORY
I01	RHEUMATIC FEVER WITH HEART INVOLVEMENT	Acute rheumatic fever
I01.0	ACUTE RHEUMATIC PERICARDITIS	Acute rheumatic fever
I01.1	ACUTE RHEUMATIC ENDOCARDITIS	Acute rheumatic fever
I01.2	ACUTE RHEUMATIC MYOCARDITIS	Acute rheumatic fever
I01.8	OTHER ACUTE RHEUMATIC HEART DISEASE	Acute rheumatic fever
I01.9	RHEUMATIC FEVER WITH HEART INVOLVEMENT	Acute rheumatic fever
I02.0	ACUTE RHEUMATIC FEVER	Acute rheumatic fever
I05	RHEUMATIC MITRAL VALVE DISEASES	Chronic rheumatic heart diseases
I05.0	RHEUMATIC MITRAL STENOSIS	Chronic rheumatic heart diseases
I05.1	RHEUMATIC MITRAL VALVE DISEASES	Chronic rheumatic heart diseases
I05.2	RHEUMATIC MITRAL VALVE DISEASES	Chronic rheumatic heart diseases
I05.8	RHEUMATIC MITRAL VALVE DISEASES	Chronic rheumatic heart diseases
I05.9	RHEUMATIC MITRAL VALVE DISEASE UNS	Chronic rheumatic heart diseases
I06	RHEUMATIC AORTIC VALVE DISEASES	Chronic rheumatic heart diseases
I06.0	RHEUMATIC AORTIC STENOSIS	Chronic rheumatic heart diseases
I06.1	RHEUMATIC AORTIC INSUFFICIENCY	Chronic rheumatic heart diseases
I06.2	RHEUMATIC AORTIC STENOSIS W/INSUFF	Chronic rheumatic heart diseases
I06.8	OTH RHEUMATIC AORTIC VALVE DISEASES	Chronic rheumatic heart diseases
I06.9	RHEUMATIC AORTIC VALVE DISEASES	Chronic rheumatic heart diseases
I07	RHEUMATIC TRICUSPID VALVE DISEASES	Chronic rheumatic heart diseases
I07.0	RHEUMATIC TRICUSPID STENOSIS	Chronic rheumatic heart diseases
I07.1	RHEUMATIC TRICUSPID INSUFFICIENCY	Chronic rheumatic heart diseases
I07.2	RHEUMATIC TRICSPD STENOSIS INSUFF	Chronic rheumatic heart diseases
I07.8	RHEUMATIC TRICUSPID VALVE DISEASES	Chronic rheumatic heart diseases
I07.9	RHEUMATIC TRICUSPID VALVE DZ UNS	Chronic rheumatic heart diseases
I08	MULTIPLE VALVE DISEASES	Chronic rheumatic heart diseases

I08.0	RHEUMATIC D/O MITRAL AORTIC VALVES	Chronic rheumatic heart diseases
I08.1	RHEUMATIC D/O MITRAL TRICUSPID VALV	Chronic rheumatic heart diseases
I08.2	RHEUMATIC D/O AORTIC TRICUSPID VALV	Chronic rheumatic heart diseases
I08.3	MULTIPLE VALVE DISEASES	Chronic rheumatic heart diseases
I08.8	RHEUMATIC MULTIPLE VALVE DISEASES	Chronic rheumatic heart diseases
I08.9	RHEUMATIC MULTI VALVE DISEASE UNS	Chronic rheumatic heart diseases
I09	OTHER RHEUMATIC HEART DISEASES	Chronic rheumatic heart diseases
I09.0	RHEUMATIC MYOCARDITIS	Chronic rheumatic heart diseases
I09.1	RHEUMATIC DZ ENDOCARDIUM VALVE UNS	Chronic rheumatic heart diseases
I09.2	CHRONIC RHEUMATIC PERICARDITIS	Chronic rheumatic heart diseases
I09.8	OTHER SPEC RHEUMATIC HEART DISEASES	Chronic rheumatic heart diseases
I09.81	RHEUMATIC HEART FAILURE	Chronic rheumatic heart diseases
I09.89	OTHER SPEC RHEUMATIC HEART DISEASES	Chronic rheumatic heart diseases
I09.9	RHEUMATIC HEART DISEASE UNSPECIFIED	Chronic rheumatic heart diseases
I10	ESSENTIAL PRIMARY HYPERTENSION	Hypertensive diseases
I11	HYPERTENSIVE HEART DISEASE	Hypertensive diseases
I11.0	HTN HEART DISEASE W/HEART FAIL	Hypertensive diseases
I11.9	HTN HEART DISEASE W/O HEART FAIL	Hypertensive diseases
I12	HYPERTENSIVE CHRONIC KIDNEY DISEASE	Hypertensive diseases
I12.0	HYPERTENSIVE CHRONIC KIDNEY DISEASE	Hypertensive diseases
I12.9	HTN CKD W/STAGE 1-4 CKD/UNS CKD	Hypertensive diseases
I13	HYPERTENSIVE HEART & CKD	Hypertensive diseases
I13.0	HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE	Hypertensive diseases
I13.1	HTN HEART CKD W/O HEART FAILURE	Hypertensive diseases
I13.10	HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE	Hypertensive diseases
I13.11	HTN HEART CKD W/O HEART FAILURE	Hypertensive diseases
I13.2	HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE	Hypertensive diseases
I15	SECONDARY HYPERTENSION	Hypertensive diseases
I15.0	SECONDARY HYPERTENSION	Hypertensive diseases

I15.1	HYPERTENSION SECOND OTH RENAL D/O	Hypertensive diseases
I15.2	SECONDARY HYPERTENSION	Hypertensive diseases
I15.8	SECONDARY HYPERTENSION	Hypertensive diseases
I15.9	SECONDARY HYPERTENSION	Hypertensive diseases
I16	HYPERTENSIVE CRISIS	Hypertensive diseases
I16.0	HYPERTENSIVE CRISIS	Hypertensive diseases
I16.1	HYPERTENSIVE CRISIS	Hypertensive diseases
I16.9	HYPERTENSIVE CRISIS	Hypertensive diseases
I1A	OTHER HYPERTENSION	Hypertensive diseases
I1A.0	RESISTANT HYPERTENSION	Hypertensive diseases
I20	ANGINA PECTORIS	Ischemic heart diseases
I20.0	UNSTABLE ANGINA	Ischemic heart diseases
I20.1	ANGINA PECTORIS	Ischemic heart diseases
I20.2	REFRACTORY ANGINA PECTORIS	Ischemic heart diseases
I20.8	ANGINA PECTORIS	Ischemic heart diseases
I20.81	OTHER FORMS OF ANGINA PECTORIS	Ischemic heart diseases
I20.89	OTHER FORMS OF ANGINA PECTORIS	Ischemic heart diseases
I20.9	ANGINA PECTORIS	Ischemic heart diseases
I21	ACUTE MYOCARDIAL INFARCTION	Ischemic heart diseases
I21.0	ST ELEVATION MI ANTERIOR WALL	Ischemic heart diseases
I21.01	ACUTE MYOCARDIAL INFARCTION	Ischemic heart diseases
I21.02	ST ELEVATION MI ANTERIOR WALL	Ischemic heart diseases
I21.09	ACUTE MYOCARDIAL INFARCTION	Ischemic heart diseases
I21.1	ST ELEVATION MI INFERIOR WALL	Ischemic heart diseases
I21.11	ST ELEVATION MI INFERIOR WALL	Ischemic heart diseases
I21.19	ACUTE MYOCARDIAL INFARCTION	Ischemic heart diseases
I21.2	ST ELEVATION MI OTHER SITES	Ischemic heart diseases
I21.21	ST ELEVATION MI OTHER SITES	Ischemic heart diseases
I21.29	ST ELEVATION MI OTHER SITES	Ischemic heart diseases

I21.3	ACUTE MYOCARDIAL INFARCTION	Ischemic heart diseases
I21.4	ACUTE MYOCARDIAL INFARCTION	Ischemic heart diseases
I21.9	ACUTE MYOCARDIAL INFARCTION	Ischemic heart diseases
I21.A	ACUTE MYOCARDIAL INFARCTION	Ischemic heart diseases
I21.A1	OTHER TYPE OF MYOCARDIAL INFARCTION	Ischemic heart diseases
I21.A9	OTHER TYPE OF MYOCARDIAL INFARCTION	Ischemic heart diseases
I21.B	MI W CORNRY MICROVASCULAR DYSFNCT	Ischemic heart diseases
I22	SUBSEQUENT STEMI AND NSTEMI	Ischemic heart diseases
I22.0	SUBSEQUENT ST ELEVATION MI ANT WALL	Ischemic heart diseases
I22.1	SUBSEQUENT ST ELEVATION MI INF WALL	Ischemic heart diseases
I22.2	SUBSEQUENT NON-ST ELEVATION MI	Ischemic heart diseases
I22.8	SUBSEQUENT STEMI OTHER SITE	Ischemic heart diseases
I22.9	SUBSEQUENT STEMI UNSPECIFIED SITE	Ischemic heart diseases
I23	CERTAIN CURRENT COMPLICATIONS FOLLOWING ST ELEVATION (STEMI) AND NON-ST ELEVATION (NSTEMI) MYOCARDIAL INFARCTION (WITHIN THE 28 DAY PERIOD)	Ischemic heart diseases
I23.0	HEMOPERICARDIUM CURR COMP FLW AMI	Ischemic heart diseases
I23.1	ASD AS CURR COMP FLW ACUTE MI	Ischemic heart diseases
I23.2	VSD AS CURR COMP FLW ACUTE MI	Ischemic heart diseases
I23.3	CERTAIN CURRENT COMPLICATIONS FOLLOWING ST ELEVATION (STEMI) AND NON-ST ELEVATION (NSTEMI) MYOCARDIAL INFARCTION (WITHIN THE 28 DAY PERIOD)	Ischemic heart diseases
I23.4	RUPT CT CURR COMP FLW ACUTE MI	Ischemic heart diseases
I23.5	RUPT PAP MUSC CURR COMP FLW AMI	Ischemic heart diseases
I23.6	THROMB AT AUR APP VENT COMP FLW AMI	Ischemic heart diseases
I23.7	POSTINFARCTION ANGINA	Ischemic heart diseases
I23.8	OTHER CURRENT COMP FLW ACUTE MI	Ischemic heart diseases
I24	OTHER ACUTE ISCHEMIC HEART DISEASES	Ischemic heart diseases
I24.0	OTHER ACUTE ISCHEMIC HEART DISEASES	Ischemic heart diseases
I24.1	OTHER ACUTE ISCHEMIC HEART DISEASES	Ischemic heart diseases

I24.8	OTHER ACUTE ISCHEMIC HEART DISEASES	Ischemic heart diseases
I24.81	OTHER FORMS ACUTE ISCHEMIC HEART DZ	Ischemic heart diseases
I24.89	OTHER FORMS ACUTE ISCHEMIC HEART DZ	Ischemic heart diseases
I24.9	OTHER ACUTE ISCHEMIC HEART DISEASES	Ischemic heart diseases
I25	CHRONIC ISCHEMIC HEART DISEASE	Ischemic heart diseases
I25.1	CHRONIC ISCHEMIC HEART DISEASE	Ischemic heart diseases
I25.10	CHRONIC ISCHEMIC HEART DISEASE	Ischemic heart diseases
I25.11	CHRONIC ISCHEMIC HEART DISEASE	Ischemic heart diseases
I25.110	CHRONIC ISCHEMIC HEART DISEASE	Ischemic heart diseases
I25.111	ATHEROSCLEROTIC HRT DZ NATV COR ART	Ischemic heart diseases
I25.112	ATHEROSCLEROTIC HRT DZ NATV COR ART	Ischemic heart diseases
I25.118	CHRONIC ISCHEMIC HEART DISEASE	Ischemic heart diseases
I25.119	ATHEROSCLEROTIC HRT DZ NATV COR ART	Ischemic heart diseases
I25.2	OLD MYOCARDIAL INFARCTION	Ischemic heart diseases
I25.3	ANEURYSM OF HEART	Ischemic heart diseases
I25.4	CORONARY ARTERY ANEURYSM DISSECTION	Ischemic heart diseases
I25.41	CORONARY ARTERY ANEURYSM DISSECTION	Ischemic heart diseases
I25.42	CORONARY ARTERY ANEURYSM DISSECTION	Ischemic heart diseases
I25.5	ISCHEMIC CARDIOMYOPATHY	Ischemic heart diseases
I25.6	SILENT MYOCARDIAL ISCHEMIA	Ischemic heart diseases
I25.7	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.70	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.700	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.701	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.702	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.708	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.709	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.71	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.710	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases

I25.711	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.712	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.718	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.719	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.72	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.720	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.721	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.722	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.728	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.729	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.73	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.730	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.731	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.732	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.738	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.739	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.75	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.750	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.751	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.752	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.758	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.759	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.76	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.760	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.761	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.762	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.768	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.769	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.79	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases

I25.790	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.791	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.792	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.798	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.799	ATS CABG & COR ART TRANSPL HRT W/AP	Ischemic heart diseases
I25.8	OTH FORMS CHRONIC ISCHEMIC HEART DZ	Ischemic heart diseases
I25.81	OTH FORMS CHRONIC ISCHEMIC HEART DZ	Ischemic heart diseases
I25.810	OTH FORMS CHRONIC ISCHEMIC HEART DZ	Ischemic heart diseases
I25.811	OTH FORMS CHRONIC ISCHEMIC HEART DZ	Ischemic heart diseases
I25.812	OTH FORMS CHRONIC ISCHEMIC HEART DZ	Ischemic heart diseases
I25.82	CHRONIC ISCHEMIC HEART DISEASE	Ischemic heart diseases
I25.83	OTH FORMS CHRONIC ISCHEMIC HEART DZ	Ischemic heart diseases
I25.84	OTH FORMS CHRONIC ISCHEMIC HEART DZ	Ischemic heart diseases
I25.85	OTH FORMS CHRONIC ISCHEMIC HEART DZ	Ischemic heart diseases
I25.89	OTH FORMS CHRONIC ISCHEMIC HEART DZ	Ischemic heart diseases
I25.9	CHRONIC ISCHEMIC HEART DISEASE	Ischemic heart diseases
I26	PULMONARY EMBOLISM	Pulmonary heart disease and diseases of pulmonary circulation
I26.0	PULM EMBO W/ACUTE COR PULMONALE	Pulmonary heart disease and diseases of pulmonary circulation
I26.01	PULM EMBO W/ACUTE COR PULMONALE	Pulmonary heart disease and diseases of pulmonary circulation
I26.02	PULM EMBO W/ACUTE COR PULMONALE	Pulmonary heart disease and diseases of pulmonary circulation
I26.09	PULM EMBO W/ACUTE COR PULMONALE	Pulmonary heart disease and diseases of pulmonary circulation
I26.9	PULM EMBO W/O ACUTE COR PULMONALE	Pulmonary heart disease and diseases of pulmonary circulation
I26.90	PULM EMBO W/O ACUTE COR PULMONALE	Pulmonary heart disease and diseases of pulmonary circulation
I26.92	PULMONARY EMBOLISM	Pulmonary heart disease and diseases of pulmonary circulation
I26.93	PULM EMBO W/O ACUTE COR PULMONALE	Pulmonary heart disease and diseases of pulmonary circulation
I26.94	PULMONARY EMBOLISM	Pulmonary heart disease and diseases of pulmonary circulation
I26.99	PULM EMBO W/O ACUTE COR PULMONALE	Pulmonary heart disease and diseases of pulmonary circulation
I27	OTHER PULMONARY HEART DISEASES	Pulmonary heart disease and diseases of pulmonary circulation
I27.0	OTHER PULMONARY HEART DISEASES	Pulmonary heart disease and diseases of pulmonary circulation

I27.1	KYPHOSCOLIOTIC HEART DISEASE	Pulmonary heart disease and diseases of pulmonary circulation
I27.2	OTHER SECOND PULMONARY HYPERTENSION	Pulmonary heart disease and diseases of pulmonary circulation
I27.20	OTHER SEC PULMONARY HYPERTENSION	Pulmonary heart disease and diseases of pulmonary circulation
I27.21	OTHER SEC PULMONARY HYPERTENSION	Pulmonary heart disease and diseases of pulmonary circulation
I27.22	OTHER SEC PULMONARY HYPERTENSION	Pulmonary heart disease and diseases of pulmonary circulation
I27.23	OTHER SEC PULMONARY HYPERTENSION	Pulmonary heart disease and diseases of pulmonary circulation
I27.24	OTHER PULMONARY HEART DISEASES	Pulmonary heart disease and diseases of pulmonary circulation
I27.29	OTHER PULMONARY HEART DISEASES	Pulmonary heart disease and diseases of pulmonary circulation
I27.8	OTHER SPECIFIED PULMONARY HEART DZ	Pulmonary heart disease and diseases of pulmonary circulation
I27.81	OTHER PULMONARY HEART DISEASES	Pulmonary heart disease and diseases of pulmonary circulation
I27.82	OTHER PULMONARY HEART DISEASES	Pulmonary heart disease and diseases of pulmonary circulation
I27.83	OTHER SPECIFIED PULMONARY HEART DZ	Pulmonary heart disease and diseases of pulmonary circulation
I27.89	OTHER PULMONARY HEART DISEASES	Pulmonary heart disease and diseases of pulmonary circulation
I27.9	OTHER PULMONARY HEART DISEASES	Pulmonary heart disease and diseases of pulmonary circulation
I28	OTHER DISEASES OF PULMONARY VESSELS	Pulmonary heart disease and diseases of pulmonary circulation
I28.0	OTHER DISEASES OF PULMONARY VESSELS	Pulmonary heart disease and diseases of pulmonary circulation
I28.1	ANEURYSM OF PULMONARY ARTERY	Pulmonary heart disease and diseases of pulmonary circulation
I28.8	OTHER DISEASES OF PULMONARY VESSELS	Pulmonary heart disease and diseases of pulmonary circulation
I28.9	DISEASE PULMONARY VESSELS UNS	Other forms of heart disease
I30	ACUTE PERICARDITIS	Other forms of heart disease
I30.0	AC NONSPECIFIC IDIOPATH PERICARDIT	Other forms of heart disease
I30.1	ACUTE PERICARDITIS	Other forms of heart disease
I30.8	OTHER FORMS OF ACUTE PERICARDITIS	Other forms of heart disease
I30.9	ACUTE PERICARDITIS	Other forms of heart disease
I31	OTHER DISEASES OF PERICARDIUM	Other forms of heart disease
I31.0	CHRONIC ADHESIVE PERICARDITIS	Other forms of heart disease
I31.1	CHRONIC CONSTRICTIVE PERICARDITIS	Other forms of heart disease
I31.2	HEMOPERICARDIUM NEC	Other forms of heart disease
I31.3	OTHER DISEASES OF PERICARDIUM	Other forms of heart disease

I31.31	PERICARDIAL EFFUSION NONINFLAMM	Other forms of heart disease
I31.39	PERICARDIAL EFFUSION NONINFLAMM	Other forms of heart disease
I31.4	CARDIAC TAMPONADE	Other forms of heart disease
I31.8	OTHER SPEC DISEASES PERICARDIUM	Other forms of heart disease
I31.9	OTHER DISEASES OF PERICARDIUM	Other forms of heart disease
I32	PERICARDITIS DZ CLASS ELSEWHERE	Other forms of heart disease
I33	ACUTE AND SUBACUTE ENDOCARDITIS	Other forms of heart disease
I33.0	ACUTE AND SUBACUTE ENDOCARDITIS	Other forms of heart disease
I33.9	ACUTE & SUBACUTE ENDOCARDITIS UNS	Other forms of heart disease
I34	NONRHEUMATIC MITRAL VALVE DISORDERS	Other forms of heart disease
I34.0	NONRHEUMATIC MITRAL INSUFFICIENCY	Other forms of heart disease
I34.1	NONRHEUMATIC MITRAL VALVE PROLAPSE	Other forms of heart disease
I34.2	NONRHEUMATIC MITRAL VALVE STENOSIS	Other forms of heart disease
I34.8	NONRHEUMATIC MITRAL VALVE DISORDERS	Other forms of heart disease
I34.81	OTH NONRHEUMATIC MITRAL VALVE D/O	Other forms of heart disease
I34.89	OTH NONRHEUMATIC MITRAL VALVE D/O	Other forms of heart disease
I34.9	NONRHEUMATIC MITRAL VALVE D/O UNS	Other forms of heart disease
I35	NONRHEUMATIC AORTIC VALVE DISORDERS	Other forms of heart disease
I35.0	NONRHEUMATIC AORTIC VALVE STENOSIS	Other forms of heart disease
I35.1	NONRHEUMATIC AORTIC VALVE DISORDERS	Other forms of heart disease
I35.2	NONRHEUMATIC AV STENOS W/INSUFF	Other forms of heart disease
I35.8	OTH NONRHEUMATIC AORTIC VALVE D/O	Other forms of heart disease
I35.9	NONRHEUMATIC AORTIC VALVE D/O UNS	Other forms of heart disease
I36	NONRHEUMATIC TRICUSPID VALVE DISORDERS	Other forms of heart disease
I36.0	NONRHEUMATIC TRICUSPID VALV STENOSIS	Other forms of heart disease
I36.1	NONRHEUMATIC TRICUSPID VALVE DISORDERS	Other forms of heart disease
I36.2	NONRHEUMATIC TV STENOS W/INSUFF	Other forms of heart disease
I36.8	NONRHEUMATIC TRICUSPID VALVE DISORDERS	Other forms of heart disease
I36.9	NONRHEUMATIC TRICUSPID VALVE DISORDERS	Other forms of heart disease

I37	NONRHEUMATIC PULMONARY VALVE D/O	Other forms of heart disease
I37.0	NONRHEUMATIC PULM VALVE STENOSIS	Other forms of heart disease
I37.1	NONRHEUMATIC PULMONARY VALVE INSUFF	Other forms of heart disease
I37.2	NONRHEUMATIC PV STENOS W/INSUFF	Other forms of heart disease
I37.8	OTH NONRHEUMATIC PULMONARY VALV D/O	Other forms of heart disease
I37.9	NONRHEUMATIC PULM VALV DISORDER UNS	Other forms of heart disease
I38	ENDOCARDITIS, VALVE UNSPECIFIED	Other forms of heart disease
I39	ENDOCARDIT HRT VLV D/O DZ CLSS ELSW	Other forms of heart disease
I40	ACUTE MYOCARDITIS	Other forms of heart disease
I40.0	INFECTIVE MYOCARDITIS	Other forms of heart disease
I40.1	ACUTE MYOCARDITIS	Other forms of heart disease
I40.8	OTHER ACUTE MYOCARDITIS	Other forms of heart disease
I40.9	ACUTE MYOCARDITIS UNSPECIFIED	Other forms of heart disease
I41	MYOCARDITIS DZ CLASSIFIED ELSEWHERE	Other forms of heart disease
I42	CARDIOMYOPATHY	Other forms of heart disease
I42.0	CARDIOMYOPATHY	Other forms of heart disease
I42.1	OBST HYPERTROPHIC CARDIOMYOPATHY	Other forms of heart disease
I42.2	OTHER HYPERTROPHIC CARDIOMYOPATHY	Other forms of heart disease
I42.3	ENDOMYOCARDIAL EOSINOPHILIC DISEASE	Other forms of heart disease
I42.4	ENDOCARDIAL FIBROELASTOSIS	Other forms of heart disease
I42.5	OTHER RESTRICTIVE CARDIOMYOPATHY	Other forms of heart disease
I42.6	ALCOHOLIC CARDIOMYOPATHY	Other forms of heart disease
I42.7	CARDIOMYOPATHY D/T DRUG EXT AGENT	Other forms of heart disease
I42.8	CARDIOMYOPATHY	Other forms of heart disease
I42.9	CARDIOMYOPATHY	Other forms of heart disease
I43	CARDIOMYOPATHY IN DISEASES CLASSIFIED ELSEWHERE	Other forms of heart disease
I44	ATRIOVENTRICULAR AND LEFT BBB	Other forms of heart disease
I44.0	ATRIOVENTRICULAR BLOCK FIRST DEGREE	Other forms of heart disease
I44.1	ATRIOVENTRICULAR BLOCK SECOND DEG	Other forms of heart disease

I44.2	ATRIOVENTRICULAR AND LEFT BUNDLE-BRANCH BLOCK	Other forms of heart disease
I44.3	ATRIOVENTRICULAR AND LEFT BUNDLE-BRANCH BLOCK	Other forms of heart disease
I44.30	OTHER & UNS ATRIOVENTRICULAR BLOCK	Other forms of heart disease
I44.39	OTHER & UNS ATRIOVENTRICULAR BLOCK	Other forms of heart disease
I44.4	ATRIOVENTRICULAR AND LEFT BUNDLE-BRANCH BLOCK	Other forms of heart disease
I44.5	LEFT POSTERIOR FASCICULAR BLOCK	Other forms of heart disease
I44.6	OTHER & UNS FASCICULAR BLOCK	Other forms of heart disease
I44.60	OTHER & UNS FASCICULAR BLOCK	Other forms of heart disease
I44.69	ATRIOVENTRICULAR AND LEFT BUNDLE-BRANCH BLOCK	Other forms of heart disease
I44.7	ATRIOVENTRICULAR AND LEFT BUNDLE-BRANCH BLOCK	Other forms of heart disease
I45	OTHER CONDUCTION DISORDERS	Other forms of heart disease
I45.0	OTHER CONDUCTION DISORDERS	Other forms of heart disease
I45.1	OTHER & UNS RT BUNDLE-BRANCH BLOCK	Other forms of heart disease
I45.10	OTHER & UNS RT BUNDLE-BRANCH BLOCK	Other forms of heart disease
I45.19	OTHER CONDUCTION DISORDERS	Other forms of heart disease
I45.2	OTHER CONDUCTION DISORDERS	Other forms of heart disease
I45.3	TRIFASCICULAR BLOCK	Other forms of heart disease
I45.4	NONSPECIFIC INTRAVENTRICULAR BLOCK	Other forms of heart disease
I45.5	OTHER CONDUCTION DISORDERS	Other forms of heart disease
I45.6	OTHER CONDUCTION DISORDERS	Other forms of heart disease
I45.8	OTHER SPEC CONDUCTION DISORDERS	Other forms of heart disease
I45.81	OTHER SPEC CONDUCTION DISORDERS	Other forms of heart disease
I45.89	OTHER SPEC CONDUCTION DISORDERS	Other forms of heart disease
I45.9	OTHER CONDUCTION DISORDERS	Other forms of heart disease
I46	CARDIAC ARREST	Other forms of heart disease
I46.2	CARDIAC ARREST	Other forms of heart disease
I46.8	CARDIAC ARREST	Other forms of heart disease
I46.9	CARDIAC ARREST	Other forms of heart disease
I47	PAROXYSMAL TACHYCARDIA	Other forms of heart disease

I47.0	PAROXYSMAL TACHYCARDIA	Other forms of heart disease
I47.1	SUPRAVENTRICULAR TACHYCARDIA	Other forms of heart disease
I47.10	SUPRAVENTRICULAR TACHYCARDIA	Other forms of heart disease
I47.11	SUPRAVENTRICULAR TACHYCARDIA	Other forms of heart disease
I47.19	PAROXYSMAL TACHYCARDIA	Other forms of heart disease
I47.2	VENTRICULAR TACHYCARDIA	Other forms of heart disease
I47.20	PAROXYSMAL TACHYCARDIA	Other forms of heart disease
I47.21	VENTRICULAR TACHYCARDIA	Other forms of heart disease
I47.29	PAROXYSMAL TACHYCARDIA	Other forms of heart disease
I47.9	PAROXYSMAL TACHYCARDIA UNSPECIFIED	Other forms of heart disease
I48	ATRIAL FIBRILLATION AND FLUTTER	Other forms of heart disease
I48.0	ATRIAL FIBRILLATION AND FLUTTER	Other forms of heart disease
I48.1	ATRIAL FIBRILLATION AND FLUTTER	Other forms of heart disease
I48.11	ATRIAL FIBRILLATION AND FLUTTER	Other forms of heart disease
I48.19	ATRIAL FIBRILLATION AND FLUTTER	Other forms of heart disease
I48.2	ATRIAL FIBRILLATION AND FLUTTER	Other forms of heart disease
I48.20	CHRONIC ATRIAL FIBRILLATION	Other forms of heart disease
I48.21	CHRONIC ATRIAL FIBRILLATION	Other forms of heart disease
I48.3	TYPICAL ATRIAL FLUTTER	Other forms of heart disease
I48.4	ATRIAL FIBRILLATION AND FLUTTER	Other forms of heart disease
I48.9	UNS ATR FIBRILLATION ATRIAL FLUTTER	Other forms of heart disease
I48.91	ATRIAL FIBRILLATION AND FLUTTER	Other forms of heart disease
I48.92	ATRIAL FIBRILLATION AND FLUTTER	Other forms of heart disease
I49	OTHER CARDIAC ARRHYTHMIAS	Other forms of heart disease
I49.0	OTHER CARDIAC ARRHYTHMIAS	Other forms of heart disease
I49.01	OTHER CARDIAC ARRHYTHMIAS	Other forms of heart disease
I49.02	VENTRICULAR FIBRILLATION & FLUTTER	Other forms of heart disease
I49.1	ATRIAL PREMATURE DEPOLARIZATION	Other forms of heart disease
I49.2	JUNCTIONAL PREMATURE DEPOLARIZATION	Other forms of heart disease

I49.3	OTHER CARDIAC ARRHYTHMIAS	Other forms of heart disease
I49.4	OTHER UNS PREMATURE DEPOLARIZATION	Other forms of heart disease
I49.40	OTHER CARDIAC ARRHYTHMIAS	Other forms of heart disease
I49.49	OTHER UNS PREMATURE DEPOLARIZATION	Other forms of heart disease
I49.5	OTHER CARDIAC ARRHYTHMIAS	Other forms of heart disease
I49.8	OTHER CARDIAC ARRHYTHMIAS	Other forms of heart disease
I49.9	OTHER CARDIAC ARRHYTHMIAS	Other forms of heart disease
I50	HEART FAILURE	Other forms of heart disease
I50.1	HEART FAILURE	Other forms of heart disease
I50.2	HEART FAILURE	Other forms of heart disease
I50.20	HEART FAILURE	Other forms of heart disease
I50.21	HEART FAILURE	Other forms of heart disease
I50.22	HEART FAILURE	Other forms of heart disease
I50.23	SYSTOLIC CONGESTIVE HEART FAILURE	Other forms of heart disease
I50.3	DIASTOLIC CONGESTIVE HEART FAILURE	Other forms of heart disease
I50.30	DIASTOLIC CONGESTIVE HEART FAILURE	Other forms of heart disease
I50.31	DIASTOLIC CONGESTIVE HEART FAILURE	Other forms of heart disease
I50.32	DIASTOLIC CONGESTIVE HEART FAILURE	Other forms of heart disease
I50.33	HEART FAILURE	Other forms of heart disease
I50.4	COMBINED SYSTOLIC & DIASTOLIC CHF	Other forms of heart disease
I50.40	HEART FAILURE	Other forms of heart disease
I50.41	COMBINED SYSTOLIC & DIASTOLIC CHF	Other forms of heart disease
I50.42	COMBINED SYSTOLIC & DIASTOLIC CHF	Other forms of heart disease
I50.43	HEART FAILURE	Other forms of heart disease
I50.8	HEART FAILURE	Other forms of heart disease
I50.81	HEART FAILURE	Other forms of heart disease
I50.810	OTHER HEART FAILURE	Other forms of heart disease
I50.811	OTHER HEART FAILURE	Other forms of heart disease
I50.812	OTHER HEART FAILURE	Other forms of heart disease

I50.813	OTHER HEART FAILURE	Other forms of heart disease
I50.814	OTHER HEART FAILURE	Other forms of heart disease
I50.82	OTHER HEART FAILURE	Other forms of heart disease
I50.83	OTHER HEART FAILURE	Other forms of heart disease
I50.84	OTHER HEART FAILURE	Other forms of heart disease
I50.89	OTHER HEART FAILURE	Other forms of heart disease
I50.9	HEART FAILURE	Other forms of heart disease
I51	COMP ILL-DEFINED DESC HEART DISEASE	Other forms of heart disease
I51.0	COMPLICATIONS AND ILL-DEFINED DESCRIPTIONS OF HEART DISEASE	Other forms of heart disease
I51.1	COMPLICATIONS AND ILL-DEFINED DESCRIPTIONS OF HEART DISEASE	Other forms of heart disease
I51.2	COMPLICATIONS AND ILL-DEFINED DESCRIPTIONS OF HEART DISEASE	Other forms of heart disease
I51.3	INTRACARDIAC THROMBOSIS NEC	Other forms of heart disease
I51.4	MYOCARDITIS UNSPECIFIED	Other forms of heart disease
I51.5	MYOCARDIAL DEGENERATION	Other forms of heart disease
I51.7	COMPLICATIONS AND ILL-DEFINED DESCRIPTIONS OF HEART DISEASE	Other forms of heart disease
I51.8	OTHER ILL-DEFINED HEART DISEASES	Other forms of heart disease
I51.81	OTHER ILL-DEFINED HEART DISEASES	Other forms of heart disease
I51.89	OTHER ILL-DEFINED HEART DISEASES	Other forms of heart disease
I51.9	COMPLICATIONS AND ILL-DEFINED DESCRIPTIONS OF HEART DISEASE	Other forms of heart disease
I52	OTH HEART D/O DZ CLASSIFIED ELSW	Other forms of heart disease
I5A	NON-ISCHEMIC MYOCARDIAL INJURY (NON-TRAUM)	Other forms of heart disease
I63.019	CEREBRAL INFARCTION	Diseases of arteries, arterioles and capillaries
I70.0	ATHEROSCLEROSIS OF AORTA	Diseases of arteries, arterioles and capillaries
I70.1	ATHEROSCLEROSIS OF RENAL ARTERY	Diseases of arteries, arterioles and capillaries
I70.2	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.20	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries

I63.59	CEREBRAL INFARCTION	Diseases of arteries, arterioles and capillaries
I70.202	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.203	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.208	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I65.03	OCCLUSION AND STENOSIS OF PRECEREBRAL ARTERIES, NOT RESULTING IN CEREBRAL INFARCTION	Diseases of arteries, arterioles and capillaries
I70.21	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I65.1	OCCLUSION AND STENOSIS OF PRECEREBRAL ARTERIES, NOT RESULTING IN CEREBRAL INFARCTION	Diseases of arteries, arterioles and capillaries
I70.212	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.213	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.218	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.219	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.22	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.221	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.222	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.223	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.228	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.229	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.23	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.231	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.232	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.233	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.234	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.235	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.238	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.239	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.24	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.241	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.242	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries

I70.243	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.244	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.245	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.248	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.249	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.25	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.26	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I65.22	OCCLUSION AND STENOSIS OF PRECEREBRAL ARTERIES, NOT RESULTING IN CEREBRAL INFARCTION	Diseases of arteries, arterioles and capillaries
I65.23	OCCLUSION AND STENOSIS OF PRECEREBRAL ARTERIES, NOT RESULTING IN CEREBRAL INFARCTION	Diseases of arteries, arterioles and capillaries
I70.263	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.268	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.269	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.29	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.291	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.292	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.293	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.298	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.299	ATHEROSCLEROSIS NATV ART EXTREM	Diseases of arteries, arterioles and capillaries
I70.3	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I65.8	OCCLUSION AND STENOSIS OF PRECEREBRAL ARTERIES, NOT RESULTING IN CEREBRAL INFARCTION	Diseases of arteries, arterioles and capillaries
I70.301	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.302	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.303	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.308	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.309	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.31	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.311	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries

I70.362	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.363	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.368	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.369	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.39	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.391	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.392	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.393	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.398	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.399	ATHSC UNS TYPE BYPASS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.4	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I66.0	OCCLUSION AND STENOSIS OF CEREBRAL ARTERIES, NOT RESULTING IN CEREBRAL INFARCTION	Diseases of arteries, arterioles and capillaries
I70.401	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.402	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.403	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.408	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.409	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.41	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.411	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.412	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.413	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.418	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.419	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.42	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.421	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.422	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.423	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I70.428	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries

I70.499	ATHSC AUTOL VEIN BYPS GRAFT EXTREM	Diseases of arteries, arterioles and capillaries
I66.9	OCCLUSION AND STENOSIS OF CEREBRAL ARTERIES, NOT RESULTING IN CEREBRAL INFARCTION	Diseases of arteries, arterioles and capillaries
I70.50	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.501	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.502	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.503	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.508	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.509	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.51	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.511	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.512	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.513	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.518	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.519	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.52	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.521	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.522	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.523	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.528	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.529	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.53	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.531	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.532	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.533	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.534	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.535	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.538	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.539	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries

I70.54	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.541	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.542	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.543	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.544	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.545	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.548	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.549	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.55	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.56	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.561	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.562	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.563	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.568	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.569	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.59	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.591	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.592	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.593	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.598	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.599	ATHEROSCLER NONAUTO BIO BP GFT EXT	Diseases of arteries, arterioles and capillaries
I70.6	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.60	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.601	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.602	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.603	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.608	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.609	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70	ATHEROSCLEROSIS	Diseases of arteries, arterioles and capillaries

I70.661	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.662	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.663	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.668	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.669	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.69	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.691	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.692	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.693	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.698	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.699	OTH ATHSC NONBIOLOGICL BP GRAFT EXT	Diseases of arteries, arterioles and capillaries
I70.7	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.70	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.701	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.702	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.703	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.708	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.709	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.201	ATHEROSCLEROSIS	Diseases of arteries, arterioles and capillaries
I70.711	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.712	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.713	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.718	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.719	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.72	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.721	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.722	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.723	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.728	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries

I70.729	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.73	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.731	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.732	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.733	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.734	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.735	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.738	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.739	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.74	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.741	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.742	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.743	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.744	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.745	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.748	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.749	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.75	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.76	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.761	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.762	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.763	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.768	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.769	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.209	ATHEROSCLEROSIS	Diseases of arteries, arterioles and capillaries
I70.791	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.792	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.793	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.798	ATHEROSCLER OTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries

I70.799	ATHEROSCLEROTH TYPE BP GRAFT EXTRM	Diseases of arteries, arterioles and capillaries
I70.8	ATHEROSCLEROSIS OF OTHER ARTERIES	Diseases of arteries, arterioles and capillaries
I70.9	OTHER & UNSPECIFIED ATHEROSCLEROSIS	Diseases of arteries, arterioles and capillaries
I70.211	ATHEROSCLEROSIS	Diseases of arteries, arterioles and capillaries
I70.261	ATHEROSCLEROSIS	Diseases of arteries, arterioles and capillaries
I70.92	OTHER & UNSPECIFIED ATHEROSCLEROSIS	Diseases of arteries, arterioles and capillaries
I71	AORTIC ANEURYSM AND DISSECTION	Diseases of arteries, arterioles and capillaries
I70.262	ATHEROSCLEROSIS	Diseases of arteries, arterioles and capillaries
I71.00	DISSECTION OF AORTA	Diseases of arteries, arterioles and capillaries
I71.01	DISSECTION OF AORTA	Diseases of arteries, arterioles and capillaries
I71.010	DISSECTION OF AORTA	Diseases of arteries, arterioles and capillaries
I71.011	DISSECTION OF AORTA	Diseases of arteries, arterioles and capillaries
I71.012	DISSECTION OF AORTA	Diseases of arteries, arterioles and capillaries
I71.019	DISSECTION OF AORTA	Diseases of arteries, arterioles and capillaries
I70.30	ATHEROSCLEROSIS	Diseases of arteries, arterioles and capillaries
I71.03	DISSECTION OF AORTA	Diseases of arteries, arterioles and capillaries
I71.1	THORACIC AORTIC ANEURYSM RUPTURED	Diseases of arteries, arterioles and capillaries
I71.10	THORACIC AORTIC ANEURYSM RUPTURED	Diseases of arteries, arterioles and capillaries
I71.11	THORACIC AORTIC ANEURYSM RUPTURED	Diseases of arteries, arterioles and capillaries
I71.12	THORACIC AORTIC ANEURYSM RUPTURED	Diseases of arteries, arterioles and capillaries
I71.13	THORACIC AORTIC ANEURYSM RUPTURED	Diseases of arteries, arterioles and capillaries
I70.40	ATHEROSCLEROSIS	Diseases of arteries, arterioles and capillaries
I71.20	THORACIC AORTIC ANEUR W/O RUPTURE	Diseases of arteries, arterioles and capillaries
I71.21	THORACIC AORTIC ANEUR W/O RUPTURE	Diseases of arteries, arterioles and capillaries
I71.22	THORACIC AORTIC ANEUR W/O RUPTURE	Diseases of arteries, arterioles and capillaries
I71.23	THORACIC AORTIC ANEUR W/O RUPTURE	Diseases of arteries, arterioles and capillaries
I70.5	ATHEROSCLEROSIS	Diseases of arteries, arterioles and capillaries
I71.30	ABDOMINAL AORTIC ANEURYSM RUPTURED	Diseases of arteries, arterioles and capillaries
I71.31	ABDOMINAL AORTIC ANEURYSM RUPTURED	Diseases of arteries, arterioles and capillaries

I71.32	ABDOMINAL AORTIC ANEURYSM RUPTURED	Diseases of arteries, arterioles and capillaries
I71.33	ABDOMINAL AORTIC ANEURYSM RUPTURED	Diseases of arteries, arterioles and capillaries
I70.61	ATHEROSCLEROSIS	Diseases of arteries, arterioles and capillaries
I71.40	ABDOMINAL AORTIC ANEUR W/O RUPTURE	Diseases of arteries, arterioles and capillaries
I71.41	ABDOMINAL AORTIC ANEUR W/O RUPTURE	Diseases of arteries, arterioles and capillaries
I71.42	ABDOMINAL AORTIC ANEUR W/O RUPTURE	Diseases of arteries, arterioles and capillaries
I71.43	ABDOMINAL AORTIC ANEUR W/O RUPTURE	Diseases of arteries, arterioles and capillaries
I71.5	THORACOABDOMINAL AA RUPTURED	Diseases of arteries, arterioles and capillaries
I71.50	THORACOABDOMINAL AA RUPTURED	Diseases of arteries, arterioles and capillaries
I71.51	THORACOABDOMINAL AA RUPTURED	Diseases of arteries, arterioles and capillaries
I71.52	THORACOABDOMINAL AA RUPTURED	Diseases of arteries, arterioles and capillaries
I71.6	THORACOABDOMINAL AA W/O RUPTURE	Diseases of arteries, arterioles and capillaries
I71.60	THORACOABDOMINAL AA W/O RUPTURE	Diseases of arteries, arterioles and capillaries
I71.61	THORACOABDOMINAL AA W/O RUPTURE	Diseases of arteries, arterioles and capillaries
I71.62	THORACOABDOMINAL AA W/O RUPTURE	Diseases of arteries, arterioles and capillaries
I71.8	AORTIC ANEURYSM UNS SITE RUPTURED	Diseases of arteries, arterioles and capillaries
I71.9	AORTIC ANEUR UNS SITE W/O RUPTURE	Diseases of arteries, arterioles and capillaries
I72	OTHER ANEURYSM	Diseases of arteries, arterioles and capillaries
I72.0	ANEURYSM OF CAROTID ARTERY	Diseases of arteries, arterioles and capillaries
I70.71	ATHEROSCLEROSIS	Diseases of arteries, arterioles and capillaries
I72.2	ANEURYSM OF RENAL ARTERY	Diseases of arteries, arterioles and capillaries
I70.79	ATHEROSCLEROSIS	Diseases of arteries, arterioles and capillaries
I70.90	ATHEROSCLEROSIS	Diseases of arteries, arterioles and capillaries
I72.5	OTHER ANEURYSM	Diseases of arteries, arterioles and capillaries
I72.6	OTHER ANEURYSM	Diseases of arteries, arterioles and capillaries
I70.91	ATHEROSCLEROSIS	Diseases of arteries, arterioles and capillaries
I71.0	AORTIC ANEURYSM AND DISSECTION	Diseases of arteries, arterioles and capillaries
I73	OTHER PERIPHERAL VASCULAR DISEASES	Diseases of arteries, arterioles and capillaries
I73.0	RAYNAUDS SYNDROME	Diseases of arteries, arterioles and capillaries

I71.02	AORTIC ANEURYSM AND DISSECTION	Diseases of arteries, arterioles and capillaries
I73.01	RAYNAUDS SYNDROME	Diseases of arteries, arterioles and capillaries
I73.1	THROMBOANGIITIS OBLITERANS	Diseases of arteries, arterioles and capillaries
I71.2	AORTIC ANEURYSM AND DISSECTION	Diseases of arteries, arterioles and capillaries
I71.3	AORTIC ANEURYSM AND DISSECTION	Diseases of arteries, arterioles and capillaries
I73.89	OTH SPEC PERIPHERAL VASC DISEASES	Diseases of arteries, arterioles and capillaries
I73.9	PERIPHERAL VASCULAR DISEASE UNS	Diseases of arteries, arterioles and capillaries
I74	ARTERIAL EMBOLISM AND THROMBOSIS	Diseases of arteries, arterioles and capillaries
I74.0	EMBOLISM THROMBOSIS ABDOMINAL AORTA	Diseases of arteries, arterioles and capillaries
I74.01	EMBOLISM THROMBOSIS ABDOMINAL AORTA	Diseases of arteries, arterioles and capillaries
I74.09	EMBOLISM THROMBOSIS ABDOMINAL AORTA	Diseases of arteries, arterioles and capillaries
I74.1	EMBOLISM THROMB OTH UNS PARTS AORTA	Diseases of arteries, arterioles and capillaries
I74.10	EMBOLISM THROMB OTH UNS PARTS AORTA	Diseases of arteries, arterioles and capillaries
I74.11	EMBOLISM THROMB OTH UNS PARTS AORTA	Diseases of arteries, arterioles and capillaries
I74.19	EMBOLISM THROMB OTH UNS PARTS AORTA	Diseases of arteries, arterioles and capillaries
I74.2	EMBOLISM THROMBOSIS ART UP EXTREM	Diseases of arteries, arterioles and capillaries
I71.4	AORTIC ANEURYSM AND DISSECTION	Diseases of arteries, arterioles and capillaries
I74.4	EMBOLISM THROMBOSIS ART EXTREM UNS	Diseases of arteries, arterioles and capillaries
I72.1	OTHER ANEURYSM	Diseases of arteries, arterioles and capillaries
I74.8	EMBOLISM THROMBOSIS OTHER ARTERIES	Diseases of arteries, arterioles and capillaries
I74.9	EMBOLISM & THROMBOSIS UNS ARTERY	Diseases of arteries, arterioles and capillaries
I75	ATHEROEMBOLISM	Diseases of arteries, arterioles and capillaries
I75.0	ATHEROEMBOLISM OF EXTREMITIES	Diseases of arteries, arterioles and capillaries
I75.01	ATHEROEMBOLISM OF EXTREMITIES	Diseases of arteries, arterioles and capillaries
I75.011	ATHEROEMBOLISM OF EXTREMITIES	Diseases of arteries, arterioles and capillaries
I75.012	ATHEROEMBOLISM OF EXTREMITIES	Diseases of arteries, arterioles and capillaries
I75.013	ATHEROEMBOLISM OF EXTREMITIES	Diseases of arteries, arterioles and capillaries
I75.019	ATHEROEMBOLISM OF EXTREMITIES	Diseases of arteries, arterioles and capillaries
I75.02	ATHEROEMBOLISM OF EXTREMITIES	Diseases of arteries, arterioles and capillaries

I75.021	ATHEROEMBOLISM OF EXTREMITIES	Diseases of arteries, arterioles and capillaries
I75.022	ATHEROEMBOLISM OF EXTREMITIES	Diseases of arteries, arterioles and capillaries
I75.023	ATHEROEMBOLISM OF EXTREMITIES	Diseases of arteries, arterioles and capillaries
I75.029	ATHEROEMBOLISM OF EXTREMITIES	Diseases of arteries, arterioles and capillaries
I75.8	ATHEROEMBOLISM OF OTHER SITES	Diseases of arteries, arterioles and capillaries
I75.81	ATHEROEMBOLISM OF OTHER SITES	Diseases of arteries, arterioles and capillaries
I75.89	ATHEROEMBOLISM OF OTHER SITES	Diseases of arteries, arterioles and capillaries
I76	SEPTIC ARTERIAL EMBOLISM	Diseases of arteries, arterioles and capillaries
I77	OTHER DISORDERS ARTERIES ARTERIOLES	Diseases of arteries, arterioles and capillaries
I77.0	ARTERIOVENOUS FISTULA ACQUIRED	Diseases of arteries, arterioles and capillaries
I77.1	STRICTURE OF ARTERY	Diseases of arteries, arterioles and capillaries
I77.2	RUPTURE OF ARTERY	Diseases of arteries, arterioles and capillaries
I77.3	ARTERIAL FIBROMUSCULAR DYSPLASIA	Diseases of arteries, arterioles and capillaries
I77.4	CELIAC ARTERY COMPRESSION SYNDROME	Diseases of arteries, arterioles and capillaries
I77.5	NECROSIS OF ARTERY	Diseases of arteries, arterioles and capillaries
I77.6	ARTERITIS UNSPECIFIED	Diseases of arteries, arterioles and capillaries
I77.7	OTHER ARTERIAL DISSECTION	Diseases of arteries, arterioles and capillaries
I77.70	OTHER ARTERIAL DISSECTION	Diseases of arteries, arterioles and capillaries
I72.3	OTHER ANEURYSM	Diseases of arteries, arterioles and capillaries
I72.4	OTHER ANEURYSM	Diseases of arteries, arterioles and capillaries
I77.73	OTHER ARTERIAL DISSECTION	Diseases of arteries, arterioles and capillaries
I77.74	OTHER ARTERIAL DISSECTION	Diseases of arteries, arterioles and capillaries
I77.75	OTHER ARTERIAL DISSECTION	Diseases of arteries, arterioles and capillaries
I77.76	OTHER ARTERIAL DISSECTION	Diseases of arteries, arterioles and capillaries
I77.77	OTHER ARTERIAL DISSECTION	Diseases of arteries, arterioles and capillaries
I77.79	OTHER ARTERIAL DISSECTION	Diseases of arteries, arterioles and capillaries
I77.8	OTH SPEC D/O ARTERIES & ARTERIOLES	Diseases of arteries, arterioles and capillaries
I77.81	OTH SPEC D/O ARTERIES & ARTERIOLES	Diseases of arteries, arterioles and capillaries
I72.8	OTHER ANEURYSM	Diseases of arteries, arterioles and capillaries

I77.811	OTH SPEC D/O ARTERIES & ARTERIOLES	Diseases of arteries, arterioles and capillaries
I77.812	OTH SPEC D/O ARTERIES & ARTERIOLES	Diseases of arteries, arterioles and capillaries
I77.819	OTH SPEC D/O ARTERIES & ARTERIOLES	Diseases of arteries, arterioles and capillaries
I77.82	OTH SPEC D/O ARTERIES & ARTERIOLES	Diseases of arteries, arterioles and capillaries
I77.89	OTH SPEC D/O ARTERIES & ARTERIOLES	Diseases of arteries, arterioles and capillaries
I77.9	DISORDER ARTERIES & ARTERIOLES UNS	Diseases of arteries, arterioles and capillaries
I78	DISEASES OF CAPILLARIES	Diseases of arteries, arterioles and capillaries
I72.9	OTHER ANEURYSM	Diseases of arteries, arterioles and capillaries
I73.00	OTHER PERIPHERAL VASCULAR DISEASES	Diseases of arteries, arterioles and capillaries
I73.8	OTHER PERIPHERAL VASCULAR DISEASES	Diseases of arteries, arterioles and capillaries
I79	D/O ART ARTERIOL CAP DZ CLASS ELSW	Diseases of arteries, arterioles and capillaries
I79.0	ANEURYSM AORTA DZ CLASSIFIED ELSW	Diseases of arteries, arterioles and capillaries
I79.1	AORTITIS DISEASES CLASSIFIED ELSW	Diseases of arteries, arterioles and capillaries
I73.81	OTHER PERIPHERAL VASCULAR DISEASES	Diseases of arteries, arterioles and capillaries
I95	HYPOTENSION	Other and unspecified disorders of the circulatory system
I74.3	ARTERIAL EMBOLISM AND THROMBOSIS	Other and unspecified disorders of the circulatory system
I95.1	ORTHOSTATIC HYPOTENSION	Other and unspecified disorders of the circulatory system
I74.5	ARTERIAL EMBOLISM AND THROMBOSIS	Other and unspecified disorders of the circulatory system
I95.3	HYPOTENSION OF HEMODIALYSIS	Other and unspecified disorders of the circulatory system
I95.8	OTHER HYPOTENSION	Other and unspecified disorders of the circulatory system
I95.81	OTHER HYPOTENSION	Other and unspecified disorders of the circulatory system
I95.89	OTHER HYPOTENSION	Other and unspecified disorders of the circulatory system
I77.71	OTHER DISORDERS OF ARTERIES AND ARTERIOLES	Other and unspecified disorders of the circulatory system
I97	INTROP POSTPRC COMP D/O CRC SYS NEC	Other and unspecified disorders of the circulatory system
I77.72	OTHER DISORDERS OF ARTERIES AND ARTERIOLES	Other and unspecified disorders of the circulatory system
I97.1	OTH POSTPROC CARD FUNC DISTURBANCES	Other and unspecified disorders of the circulatory system
I97.11	OTH POSTPROC CARD FUNC DISTURBANCES	Other and unspecified disorders of the circulatory system
I97.110	OTH POSTPROC CARD FUNC DISTURBANCES	Other and unspecified disorders of the circulatory system
I97.111	OTH POSTPROC CARD FUNC DISTURBANCES	Other and unspecified disorders of the circulatory system

I97.12	OTH POSTPROC CARD FUNC DISTURBANCES	Other and unspecified disorders of the circulatory system
I77.810	OTHER DISORDERS OF ARTERIES AND ARTERIOLES	Other and unspecified disorders of the circulatory system
I97.121	OTH POSTPROC CARD FUNC DISTURBANCES	Other and unspecified disorders of the circulatory system
I97.13	OTH POSTPROC CARD FUNC DISTURBANCES	Other and unspecified disorders of the circulatory system
I78.0	DISEASES OF CAPILLARIES	Other and unspecified disorders of the circulatory system
I97.131	OTH POSTPROC CARD FUNC DISTURBANCES	Other and unspecified disorders of the circulatory system
I97.19	OTH POSTPROC CARD FUNC DISTURBANCES	Other and unspecified disorders of the circulatory system
I97.190	OTH POSTPROC CARD FUNC DISTURBANCES	Other and unspecified disorders of the circulatory system
I97.191	OTH POSTPROC CARD FUNC DISTURBANCES	Other and unspecified disorders of the circulatory system
I97.2	POSTMASTECTOMY LYMPHEDEMA SYNDROME	Other and unspecified disorders of the circulatory system
I97.3	POSTPROCEDURAL HYPERTENSION	Other and unspecified disorders of the circulatory system
I97.4	INTRAOP HEM CIRC SYS ORGN COMP PROC	Other and unspecified disorders of the circulatory system
I97.41	INTRAOP HEM CIRC SYS ORGN COMP PROC	Other and unspecified disorders of the circulatory system
I97.410	INTRAOP HEM CIRC SYS ORGN COMP PROC	Other and unspecified disorders of the circulatory system
I97.411	INTRAOP HEM CIRC SYS ORGN COMP PROC	Other and unspecified disorders of the circulatory system
I97.418	INTRAOP HEM CIRC SYS ORGN COMP PROC	Other and unspecified disorders of the circulatory system
I97.42	INTRAOP HEM CIRC SYS ORGN COMP PROC	Other and unspecified disorders of the circulatory system
I97.5	ACC PUNCT LAC CIRC ORGN DUR PROC	Other and unspecified disorders of the circulatory system
I78.8	DISEASES OF CAPILLARIES	Other and unspecified disorders of the circulatory system
I97.52	ACC PUNCT LAC CIRC ORGN DUR PROC	Other and unspecified disorders of the circulatory system
I78.9	DISEASES OF CAPILLARIES	Other and unspecified disorders of the circulatory system
I97.61	POSTPROC HEM CIRC SYS ORGN FLW PROC	Other and unspecified disorders of the circulatory system
I79.8	DISEASES OF CAPILLARIES	Other and unspecified disorders of the circulatory system
I97.611	POSTPROC HEM CIRC SYS ORGN FLW PROC	Other and unspecified disorders of the circulatory system
I82.290	OTHER VENOUS EMBOLISM AND THROMBOSIS	Other and unspecified disorders of the circulatory system
I97.62	POSTPROC HEM CIRC SYS ORGN FLW PROC	Other and unspecified disorders of the circulatory system
I97.620	POSTPROC HEM CIRC SYS ORGN FLW PROC	Other and unspecified disorders of the circulatory system
I97.621	POSTPROC HEM CIRC SYS ORGN FLW PROC	Other and unspecified disorders of the circulatory system
I97.622	POSTPROC HEM CIRC SYS ORGN FLW PROC	Other and unspecified disorders of the circulatory system

I97.63	POSTPROC HEM CIRC SYS ORGN FLW PROC	Other and unspecified disorders of the circulatory system
I97.630	POSTPROC HEM CIRC SYS ORGN FLW PROC	Other and unspecified disorders of the circulatory system
I97.631	POSTPROC HEM CIRC SYS ORGN FLW PROC	Other and unspecified disorders of the circulatory system
I97.638	POSTPROC HEM CIRC SYS ORGN FLW PROC	Other and unspecified disorders of the circulatory system
I97.64	POSTPROC HEM CIRC SYS ORGN FLW PROC	Other and unspecified disorders of the circulatory system
I97.640	POSTPROC HEM CIRC SYS ORGN FLW PROC	Other and unspecified disorders of the circulatory system
I97.641	POSTPROC HEM CIRC SYS ORGN FLW PROC	Other and unspecified disorders of the circulatory system
I97.648	POSTPROC HEM CIRC SYS ORGN FLW PROC	Other and unspecified disorders of the circulatory system
I82.291	OTHER VENOUS EMBOLISM AND THROMBOSIS	Other and unspecified disorders of the circulatory system
I97.71	INTRAOP CARD FUNC DISTURBANCES	Other and unspecified disorders of the circulatory system
I97.710	INTRAOP CARD FUNC DISTURBANCES	Other and unspecified disorders of the circulatory system
I95.0	HYPOTENSION	Other and unspecified disorders of the circulatory system
I97.79	INTRAOP CARD FUNC DISTURBANCES	Other and unspecified disorders of the circulatory system
I97.790	INTRAOP CARD FUNC DISTURBANCES	Other and unspecified disorders of the circulatory system
I97.791	INTRAOP CARD FUNC DISTURBANCES	Other and unspecified disorders of the circulatory system
I97.8	OTH IO POSTPROC COMP D/O CIRC NEC	Other and unspecified disorders of the circulatory system
I97.81	OTH IO POSTPROC COMP D/O CIRC NEC	Other and unspecified disorders of the circulatory system
I97.810	OTH IO POSTPROC COMP D/O CIRC NEC	Other and unspecified disorders of the circulatory system
I97.811	OTH IO POSTPROC COMP D/O CIRC NEC	Other and unspecified disorders of the circulatory system
I97.82	OTH IO POSTPROC COMP D/O CIRC NEC	Other and unspecified disorders of the circulatory system
I97.820	OTH IO POSTPROC COMP D/O CIRC NEC	Other and unspecified disorders of the circulatory system
I95.2	HYPOTENSION	Other and unspecified disorders of the circulatory system
I97.88	OTH IO POSTPROC COMP D/O CIRC NEC	Other and unspecified disorders of the circulatory system
I97.89	OTH IO POSTPROC COMP D/O CIRC NEC	Other and unspecified disorders of the circulatory system
I95.9	HYPOTENSION	Other and unspecified disorders of the circulatory system
I97.0	INTRAOPERATIVE AND POSTPROCEDURAL COMPLICATIONS AND DISORDERS OF CIRCULATORY	Other and unspecified disorders of the circulatory system
I97.120	INTRAOPERATIVE AND POSTPROCEDURAL COMPLICATIONS AND DISORDERS OF CIRCULATORY	Other and unspecified disorders of the circulatory system

I97.130	INTRAOPERATIVE AND POSTPROCEDURAL COMPLICATIONS AND DISORDERS OF CIRCULATORY	Symptoms and signs involving the circulatory and respiratory systems
I97.51	INTRAOPERATIVE AND POSTPROCEDURAL COMPLICATIONS AND DISORDERS OF CIRCULATORY	Symptoms and signs involving the circulatory and respiratory systems
R00.1	BRADYCARDIA UNSPECIFIED	Symptoms and signs involving the circulatory and respiratory systems
R00.2	PALPITATIONS	Symptoms and signs involving the circulatory and respiratory systems
I97.6	INTRAOPERATIVE AND POSTPROCEDURAL COMPLICATIONS AND DISORDERS OF CIRCULATORY	Symptoms and signs involving the circulatory and respiratory systems
I97.610	INTRAOPERATIVE AND POSTPROCEDURAL COMPLICATIONS AND DISORDERS OF CIRCULATORY	Symptoms and signs involving the circulatory and respiratory systems
R01	CARDIAC MURMURS OTH CARDIAC SOUNDS	Symptoms and signs involving the circulatory and respiratory systems
R01.0	BENIGN AND INNOCENT CARDIAC MURMURS	Symptoms and signs involving the circulatory and respiratory systems
R01.1	CARDIAC MURMUR UNSPECIFIED	Symptoms and signs involving the circulatory and respiratory systems
I97.618	INTRAOPERATIVE AND POSTPROCEDURAL COMPLICATIONS AND DISORDERS OF CIRCULATORY	Symptoms and signs involving the circulatory and respiratory systems
R03	ABNORMAL BLD-PRESS READING W/O DX	Symptoms and signs involving the circulatory and respiratory systems
R03.0	ELEVATED BP READING W/O DX HTN	Symptoms and signs involving the circulatory and respiratory systems
R03.1	NONSPECIFIC LOW BLD-PRESS READING	Symptoms and signs involving the circulatory and respiratory systems
R07	PAIN IN THROAT AND CHEST	Symptoms and signs involving the circulatory and respiratory systems
I97.7	INTRAOPERATIVE AND POSTPROCEDURAL COMPLICATIONS AND DISORDERS OF CIRCULATORY	Symptoms and signs involving the circulatory and respiratory systems
R07.2	PRECORDIAL PAIN	Symptoms and signs involving the circulatory and respiratory systems
R07.8	OTHER CHEST PAIN	Symptoms and signs involving the circulatory and respiratory systems
I97.711	INTRAOPERATIVE AND POSTPROCEDURAL COMPLICATIONS AND DISORDERS OF CIRCULATORY	Symptoms and signs involving the circulatory and respiratory systems
R07.82	OTHER CHEST PAIN	Symptoms and signs involving the circulatory and respiratory systems
R07.89	OTHER CHEST PAIN	Symptoms and signs involving the circulatory and respiratory systems
R07.9	CHEST PAIN UNSPECIFIED	Symptoms and signs involving the circulatory and respiratory systems
I82.2	EMBO THROMB VENA CAVA OTH THOR VEIN	Other venous embolism and thrombosis
I82.21	EMBO THROMB VENA CAVA OTH THOR VEIN	Other venous embolism and thrombosis
I82.210	EMBO THROMB VENA CAVA OTH THOR VEIN	Other venous embolism and thrombosis
I82.211	EMBO THROMB VENA CAVA OTH THOR VEIN	Other venous embolism and thrombosis

I82.22	EMBO THROMB VENA CAVA OTH THOR VEIN	Other venous embolism and thrombosis
I82.220	EMBO THROMB VENA CAVA OTH THOR VEIN	Other venous embolism and thrombosis
I82.221	EMBO THROMB VENA CAVA OTH THOR VEIN	Other venous embolism and thrombosis
I82.29	EMBO THROMB VENA CAVA OTH THOR VEIN	Other venous embolism and thrombosis
I97.821	INTRAOPERATIVE AND POSTPROCEDURAL COMPLICATIONS AND DISORDERS OF CIRCULATORY	Other venous embolism and thrombosis
I99	OTHER AND UNSPECIFIED DISORDERS OF CIRCULATORY SYSTEM	Other venous embolism and thrombosis
I63	CEREBRL INFARCT	Cerebrovascular diseases
I63.0	CEREBRL INFARCT THROMB PRECEREB ART	Cerebrovascular diseases
I63.00	CEREBRL INFARCT THROMB PRECEREB ART	Cerebrovascular diseases
I63.01	CEREBRL INFARCT THROMB PRECEREB ART	Cerebrovascular diseases
I63.011	CEREBRL INFARCT THROMB PRECEREB ART	Cerebrovascular diseases
I63.012	CEREBRL INFARCT THROMB PRECEREB ART	Cerebrovascular diseases
I63.013	CEREBRL INFARCT THROMB PRECEREB ART	Cerebrovascular diseases
I99.8	OTHER AND UNSPECIFIED DISORDERS OF CIRCULATORY SYSTEM	Cerebrovascular diseases
I63.02	CEREBRL INFARCT THROMB PRECEREB ART	Cerebrovascular diseases
I63.03	CEREBRL INFARCT THROMB PRECEREB ART	Cerebrovascular diseases
I63.031	CEREBRL INFARCT THROMB PRECEREB ART	Cerebrovascular diseases
I63.032	CEREBRL INFARCT THROMB PRECEREB ART	Cerebrovascular diseases
I63.033	CEREBRL INFARCT THROMB PRECEREB ART	Cerebrovascular diseases
I63.039	CEREBRL INFARCT THROMB PRECEREB ART	Cerebrovascular diseases
I63.09	CEREBRL INFARCT THROMB PRECEREB ART	Cerebrovascular diseases
I63.1	CEREBRL INFARCT THROMB PRECEREB ART	Cerebrovascular diseases
I63.10	CEREBRAL INFARCT EMBO PRECEREB ART	Cerebrovascular diseases
I63.11	CEREBRAL INFARCT EMBO PRECEREB ART	Cerebrovascular diseases
I63.111	CEREBRAL INFARCT EMBO PRECEREB ART	Cerebrovascular diseases
I63.112	CEREBRAL INFARCT EMBO PRECEREB ART	Cerebrovascular diseases
I63.113	CEREBRAL INFARCT EMBO PRECEREB ART	Cerebrovascular diseases

I63.119	CEREBRAL INFARCT EMBO PRECEREB ART	Cerebrovascular diseases
I63.12	CEREBRAL INFARCT EMBO PRECEREB ART	Cerebrovascular diseases
I63.13	CEREBRAL INFARCT EMBO PRECEREB ART	Cerebrovascular diseases
I63.131	CEREBRAL INFARCT EMBO PRECEREB ART	Cerebrovascular diseases
I63.132	CEREBRAL INFARCT EMBO PRECEREB ART	Cerebrovascular diseases
I63.133	CEREBRAL INFARCT EMBO PRECEREB ART	Cerebrovascular diseases
I63.139	CEREBRAL INFARCT EMBO PRECEREB ART	Cerebrovascular diseases
I63.19	CEREBRAL INFARCT EMBO PRECEREB ART	Cerebrovascular diseases
I63.2	CEREBRAL INFARCT EMBO PRECEREB ART	Cerebrovascular diseases
I63.20	CEREB INF UNS OCCL/STEN PRECERB ART	Cerebrovascular diseases
I63.21	CEREB INF UNS OCCL/STEN PRECERB ART	Cerebrovascular diseases
I63.211	CEREB INF UNS OCCL/STEN PRECERB ART	Cerebrovascular diseases
I63.212	CEREB INF UNS OCCL/STEN PRECERB ART	Cerebrovascular diseases
I63.213	CEREB INF UNS OCCL/STEN PRECERB ART	Cerebrovascular diseases
I63.219	CEREB INF UNS OCCL/STEN PRECERB ART	Cerebrovascular diseases
I63.22	CEREB INF UNS OCCL/STEN PRECERB ART	Cerebrovascular diseases
I63.23	CEREB INF UNS OCCL/STEN PRECERB ART	Cerebrovascular diseases
I63.231	CEREB INF UNS OCCL/STEN PRECERB ART	Cerebrovascular diseases
I63.232	CEREB INF UNS OCCL/STEN PRECERB ART	Cerebrovascular diseases
I63.233	CEREB INF UNS OCCL/STEN PRECERB ART	Cerebrovascular diseases
I63.239	CEREB INF UNS OCCL/STEN PRECERB ART	Cerebrovascular diseases
I63.29	CEREB INF UNS OCCL/STEN PRECERB ART	Cerebrovascular diseases
I63.3	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.30	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.31	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.311	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.312	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.313	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.319	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases

I63.32	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.321	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.322	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.323	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.329	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.33	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.331	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.332	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.333	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.339	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.34	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.341	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.342	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.343	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.349	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.39	CEREB INFARCT THROMB CEREBRAL ART	Cerebrovascular diseases
I63.4	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.40	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.41	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.411	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.412	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.413	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.419	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.42	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.421	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.422	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.423	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.429	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.43	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases

I63.431	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.432	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.433	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.439	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.44	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.441	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.442	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.443	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.449	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.49	CEREBRAL INFARCT EMBOLISM CEREB ART	Cerebrovascular diseases
I63.5	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.50	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.51	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.511	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.512	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.513	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.519	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.52	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.521	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.522	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.523	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.529	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.53	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.531	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.532	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.533	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.539	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.54	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.541	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases

I63.542	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.543	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I63.549	CEREB INFARCT UNS OCC/STEN CERB ART	Cerebrovascular diseases
I99.9	OTHER AND UNSPECIFIED DISORDERS OF CIRCULATORY SYSTEM	Cerebrovascular diseases
I63.6	CEREB INFARCT VENOUS THROMBOSIS	Cerebrovascular diseases
I63.8	OTHER CEREBRAL INFARCTION	Cerebrovascular diseases
I63.81	OTHER CEREBRAL INFARCTION	Cerebrovascular diseases
I63.89	OTHER CEREBRAL INFARCTION	Cerebrovascular diseases
I63.9	OTHER CEREBRAL INFARCTION	Cerebrovascular diseases
I65	OCCLUSION & STENOS UNS PRECEREB ART	Cerebrovascular diseases
I65.0	OCCLUSION & STENOSIS VERTEBRAL ART	Cerebrovascular diseases
I65.01	OCCLUSION & STENOSIS VERTEBRAL ART	Cerebrovascular diseases
I65.02	OCCLUSION & STENOSIS VERTEBRAL ART	Cerebrovascular diseases
R00	ABNORMALITIES OF HEART BEAT	Cerebrovascular diseases
I65.09	OCCLUSION & STENOSIS VERTEBRAL ART	Cerebrovascular diseases
R00.0	ABNORMALITIES OF HEART BEAT	Cerebrovascular diseases
I65.2	OCCLUSION & STENOSIS CAROTID ARTERY	Cerebrovascular diseases
I65.21	OCCLUSION & STENOSIS CAROTID ARTERY	Cerebrovascular diseases
R00.8	ABNORMALITIES OF HEART BEAT	Cerebrovascular diseases
R00.9	ABNORMALITIES OF HEART BEAT	Cerebrovascular diseases
I65.29	OCCLUSION & STENOSIS CAROTID ARTERY	Cerebrovascular diseases
R01.2	CARDIAC MURMURS AND OTHER CARDIAC SOUNDS	Cerebrovascular diseases
I65.9	OCCLUSION & STENOS UNS PRECEREB ART	Cerebrovascular diseases
I66	OCCL & STEN CEREBRAL ART NO INFARCT	Cerebrovascular diseases
R07.1	PAIN IN THROAT AND CHEST	Cerebrovascular diseases
I66.01	OCCLUSION & STENOSIS MCA	Cerebrovascular diseases
I66.02	OCCLUSION & STENOSIS MCA	Cerebrovascular diseases
I66.03	OCCLUSION & STENOSIS MCA	Cerebrovascular diseases

I66.09	OCCLUSION & STENOSIS MCA	Cerebrovascular diseases
I66.1	OCCLUSION & STENOSIS ACA	Cerebrovascular diseases
I66.11	OCCLUSION & STENOSIS ACA	Cerebrovascular diseases
I66.12	OCCLUSION & STENOSIS ACA	Cerebrovascular diseases
I66.13	OCCLUSION & STENOSIS ACA	Cerebrovascular diseases
I66.19	OCCLUSION & STENOSIS ACA	Cerebrovascular diseases
I66.2	OCCLUSION & STENOSIS PCA	Cerebrovascular diseases
I66.21	OCCLUSION & STENOSIS PCA	Cerebrovascular diseases
I66.22	OCCLUSION & STENOSIS PCA	Cerebrovascular diseases
I66.23	OCCLUSION & STENOSIS PCA	Cerebrovascular diseases
I66.29	OCCLUSION & STENOSIS PCA	Cerebrovascular diseases
I66.3	OCCLUSION & STENOS CEREBELLAR ART	Cerebrovascular diseases
I66.8	OCCLUSION & STENOS OTH CEREBRAL ART	Cerebrovascular diseases
R07.81	PAIN IN THROAT AND CHEST	Cerebrovascular diseases

Supplemental Table 2 Predictors of Time to Tafamidis Initiation by Socioeconomic Interactions

Characteristic	HR (95% CI)	P value
Sex		
Male	—	—
Female	0.38 (0.32-0.44)	<0.001
Race		
White	—	—
Black	1.05 (0.93-1.19)	0.4
SDI		
≤80	—	—
>80	0.87 (0.77-0.99)	0.041
ATTR-CM type		
ATTRwt-CM	—	—
ATTRv-CM	1.12 (0.89-1.41)	0.3
Year of diagnosis		
2019-2020	—	—
2021-2022	1.22 (1.09-1.36)	<0.001
2023-2024	1.93 (1.72-2.17)	<0.001
Age at diagnosis	1.03 (1.03-1.04)	<0.001
US region		
Northeast	—	—
Midwest	0.95 (0.86-1.05)	0.3
South	0.89 (0.79-0.99)	0.036
West	0.75 (0.65-0.88)	<0.001
Insurance type		
Medicare	—	—
Other/Unknown	1.29 (1.12-1.50)	<0.001
Disease severity		
None	—	—
Mild or minor	1.61 (1.46-1.78)	<0.001
Moderate or severe	1.50 (1.31-1.72)	<0.001
Comorbidity		
CKD	0.82 (0.75-0.90)	<0.001
COPD	0.77 (0.69-0.86)	<0.001
Coronary artery disease	1.05 (0.96-1.15)	0.2
Diabetes mellitus	0.76 (0.70-0.84)	<0.001
Diastolic heart failure	1.38 (1.26-1.51)	<0.001
Hypertension	0.81 (0.72-0.92)	<0.001

Obesity	0.87 (0.79-0.97)	0.011
Stroke	0.49 (0.43-0.55)	<0.001
Systolic heart failure	1.17 (1.07-1.28)	<0.001
Sex*race		
Female*Black	1.91 (1.54-2.38)	<0.001
Sex*SDI		
Female*SDI >80	1.13 (0.89-1.43)	0.3
Race*ATTR-CM type		
Black*ATTRv-CM	1.65 (1.24-2.20)	<0.001

ATTR-CM = transthyretin amyloid cardiomyopathy; ATTRv-CM = variant transthyretin amyloid cardiomyopathy; ATTRwt-CM = wild-type transthyretin amyloid cardiomyopathy; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; HR = hazard ratio; SDI = Social Deprivation Index.

Supplemental Table 3 Pairwise Contrasts of Sex and Race for Time to Tafamidis Initiation

Contrast	HR (95% CI)	P value
White female vs White male (reference)		
Overall	0.39 (0.33-0.45)	<0.001
ATTRwt-CM	0.39 (0.33-0.45)	<0.001
ATTRv-CM	0.39 (0.33-0.45)	<0.001
SDI ≤80	0.38 (0.32-0.44)	<0.001
SDI >80	0.43 (0.33-0.55)	<0.001
Black male vs White male (reference)		
Overall	1.10 (0.98-1.23)	0.12
ATTRwt-CM	1.05 (0.93-1.19)	0.42
ATTRv-CM	1.74 (1.32-2.30)	<0.001
SDI ≤80	1.10 (0.98-1.23)	0.12
SDI >80	1.10 (0.98-1.23)	0.12
Black male vs White female (reference)		
Overall	2.83 (2.38-3.37)	<0.001
ATTRwt-CM	2.71 (2.27-3.24)	<0.001
ATTRv-CM	4.49 (3.30-6.10)	<0.001
SDI ≤80	2.91 (2.43-3.48)	<0.001
SDI >80	2.58 (1.99-3.34)	<0.001
Black female vs White male (reference)		
Overall	0.81 (0.71-0.93)	0.003
ATTRwt-CM	0.78 (0.68-0.90)	<0.001
ATTRv-CM	1.29 (0.97-1.72)	0.08
SDI ≤80	0.79 (0.68-0.93)	0.003
SDI >80	0.89 (0.73-1.10)	0.29
Black female vs White female (reference)		
Overall	2.10 (1.73-2.54)	<0.001
ATTRwt-CM	2.01 (1.66-2.45)	<0.001
ATTRv-CM	3.33 (2.43-4.57)	<0.001
SDI ≤80	2.10 (1.73-2.54)	<0.001
SDI >80	2.10 (1.73-2.54)	<0.001
Black female vs Black male (reference)		
Overall	0.74 (0.64-0.86)	<0.001
ATTRwt-CM	0.74 (0.64-0.86)	<0.001
ATTRv-CM	0.74 (0.64-0.86)	<0.001
SDI ≤80	0.72 (0.61-0.86)	<0.001
SDI >80	0.81 (0.67-1.00)	0.05

ATTRv-CM = variant transthyretin amyloid cardiomyopathy; ATTRwt-CM = wild-type transthyretin amyloid cardiomyopathy; HR = hazard ratio; SDI = Social Deprivation Index.

Supplemental Table 4 Predictors of Time to CVH or Death by Socioeconomic Interactions

Characteristic	HR (95% CI)	P value
Sex		
Male	—	—
Female	1.2 (1.11-1.30)	<0.001
Race		
White	—	—
Black	1.05 (0.97-1.14)	0.3
SDI		
≤80	—	—
>80	1.18 (1.08-1.28)	<0.001
ATTR-CM type		
ATTRwt-CM	—	—
ATTRv-CM	1.06 (0.91-1.23)	0.4
Year of diagnosis		
2019-2020	—	—
2021-2022	0.93 (0.87-0.99)	0.032
2023-2024	0.85 (0.78-0.92)	<0.001
Age at diagnosis	1.00 (1.00-1.01)	0.2
US region		
Northeast	—	—
Midwest	0.93 (0.86-0.99)	0.03
South	0.88 (0.81-0.94)	<0.001
West	0.88 (0.80-0.96)	0.006
Insurance type		
Medicare	—	—
Other/Unknown	0.98 (0.89-1.08)	0.7
Disease severity		
None	—	—
Mild or minor	0.94 (0.88-1.00)	0.058
Moderate or severe	1.12 (1.03-1.22)	0.01
Comorbidity		
CKD	1.58 (1.48-1.67)	<0.001
COPD	1.32 (1.24-1.40)	<0.001
Coronary artery disease	1.24 (1.17-1.32)	<0.001
Diabetes mellitus	1.14 (1.08-1.21)	<0.001
Diastolic heart failure	1.36 (1.29-1.45)	<0.001
Hypertension	1.26 (1.14-1.39)	<0.001
Obesity	1.01 (0.94-1.07)	0.9

Stroke	1.80 (1.69-1.90)	<0.001
Systolic heart failure	1.39 (1.31-1.47)	<0.001
Sex*race		
Female*Black	0.98 (0.87-1.11)	0.8
Sex*SDI		
Female*SDI >80	0.83 (0.72-0.95)	0.008
Race*ATTR-CM type		
Black*ATTRv-CM	0.76 (0.62-0.94)	0.01

ATTR-CM = transthyretin amyloid cardiomyopathy; ATTRv-CM = variant transthyretin amyloid cardiomyopathy; ATTRwt-CM = wild-type transthyretin amyloid cardiomyopathy; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; CVH = cardiovascular-related hospitalization; HR = hazard ratio; SDI = Social Deprivation Index.

Supplemental Table 5 Pairwise Contrasts of Sex and Race for Time to CVH or Death by SDI Score

Contrast	HR (95% CI)	P value
White female vs White male (reference)		
Overall	1.15 (1.07-1.25)	<0.001
ATTRwt-CM	1.15 (1.07-1.25)	<0.001
ATTRv-CM	1.15 (1.07-1.25)	<0.001
SDI ≤80	1.20 (1.11-1.30)	<0.001
SDI >80	1.00 (0.87-1.15)	0.98
Black male vs White male (reference)		
Overall	1.03 (0.95-1.11)	0.54
ATTRwt-CM	1.05 (0.97-1.14)	0.26
ATTRv-CM	0.80 (0.65-0.98)	0.03
SDI ≤80	1.03 (0.95-1.11)	0.54
SDI >80	1.03 (0.95-1.11)	0.54
Black male vs White female (reference)		
Overall	0.89 (0.81-0.98)	0.01
ATTRwt-CM	0.91 (0.83-1.00)	0.05
ATTRv-CM	0.69 (0.56-0.86)	<0.001
SDI ≤80	0.85 (0.77-0.94)	0.002
SDI >80	1.03 (0.89-1.18)	0.70
Black female vs White male (reference)		
Overall	1.16 (1.07-1.26)	<0.001
ATTRwt-CM	1.19 (1.09-1.29)	<0.001
ATTRv-CM	0.91 (0.74-1.11)	0.35
SDI ≤80	1.21 (1.10-1.33)	<0.001
SDI >80	1.00 (0.89-1.14)	0.94
Black female vs White female (reference)		
Overall	1.01 (0.91-1.11)	0.90
ATTRwt-CM	1.03 (0.93-1.14)	0.57
ATTRv-CM	0.79 (0.64-0.97)	0.03
SDI ≤80	1.01 (0.91-1.11)	0.90
SDI >80	1.01 (0.91-1.11)	0.90
Black female vs Black male (reference)		
Overall	1.13 (1.03-1.24)	0.009
ATTRwt-CM	1.13 (1.03-1.24)	0.009
ATTRv-CM	1.13 (1.03-1.24)	0.009
SDI ≤80	1.18 (1.06-1.31)	0.002
SDI >80	0.98 (0.87-1.10)	0.73

ATTRv-CM = variant transthyretin amyloid cardiomyopathy; ATTRwt-CM = wild-type

transthyretin amyloid cardiomyopathy; HR = hazard ratio; SDI = Social Deprivation Index.

Supplemental Figure 1 CONSORT Flow Diagram. ATTR-CM = transthyretin amyloid cardiomyopathy.

